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PREFACE
This hypothesis that elevated concentrations of
pancreatic glucagon are involved in the development and
maintenance of insulin resistance in women with PCO, that
there is a positive relationship between concentrations in
serum of glucagon and androgens in women with PCO and that
a decrease in the serum concentrations of androgens
results in a reduced concentration of glucagon in the
peripheral plasma have been examined in these studies.
Thus, peripheral insulin resistance would be sustained as
a result of increased plasma concentrations of glucagon in
a counter-regulatory manner, but insulin would act,
unopposed, upon the ovary to promote insulin-like growth
factor-1 and androgen production.
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ABSTRACT
In order to investigate whether glucagon is
implicated in the reduced insulin sensitivity in
hyperandrogenic women, concentrations of glucagon and
insulin in serum were measured during a 75g oral glucose
tolerance test (oGTT) in 24 obese (body mass index, BMI,
>25kgm~2) and 20 non-obese women with polycystic ovary
syndrome (PCO) , and 10 obese and 13 non-obese control
subjects. The oGTT was repeated during alteration of
concentrations of endogenous androgens by administration
of buserelin, spironolactone or a combination of
cyproterone acetate and ethinyl oestradiol to women with
PCO, and by administration of goserelin or danazol to
control subjects. The relationships between glucose,
insulin, C-peptide and glucagon values and those of
testosterone, androstenedione, dehydroepiandrosterone
sulphate and sex hormone binding globulin were examined
before and during treatment. Additionally, the
relationship between basal and glucose-stimulated glucose
concentrations and that of haemoglobin A^ (HbA^) was
examined to assess the value of HbA-^ estimation for
monitoring glycaemic control in women with PCO.
Obese women with PCO had higher serum concentrations
of insulin and glucose than did non-obese women with PCO
and control subjects, but plasma concentrations of
glucagon were greater in obese control women. There were
no significant relationships between fasting
concentrations of insulin or insulin responses to oral
glucose and those of testosterone or androstenedione in
either group of PCO subjects, but the glucagon response to
oral glucose was significantly related to both
testosterone and androstenedione in obese women with PCO.
No significant relationship was demonstrated between
change in serum concentrations of androgens as a result of
treatment and those of insulin or glucagon in any of the
groups. In no case was the HbA^ concentration above
normal laboratory values although a significant
correlation between HbA^ and summed glucose levels was
apparent.
Glucagon does not appear to be implicated in the
insulin resistance exhibited by women with PCO nor do
androgens appear to directly effect concentrations of
insulin or glucagon in normal women or in those with PCO.
Measurement of HbA-t is not sufficiently discriminatory for




The definition and pathogenesis of the polycystic
ovary syndrome (PCO) have been subjects of controversy for
more than 20 years. It encompasses a group of women with
a heterogeneous collection of symptoms and signs of
variable severity and which have included some of the
following:
a) menstrual irregularity dating from the menarche;
b) oligomenorrhoea or amenorrhoea;
c) symptoms of hyperandrogenism (hirsutism, seborrhoea,
acne, and occasionally male pattern hair loss);
d) reduction of fertility;
e) obesity;
f) bilaterally enlarged or normal sized sclerocystic
ovaries;
g) elevation of serum concentrations of luteinising
hormone (LH), an increased ratio of serum concentrations
of LH to follicle stimulating hormone (FSH), elevation of
concentrations n*7 arr5^ g^nic sex Ceroid"3 and




Sclerocystic ovaries in the human were described by
Chereau in 1845 and partial resection of the sclerocystic
ovary had been performed by the turn of the 20th century
(Goldzieher 1981). Recognition of the association between
the cluster of symptoms of menstrual irregularity,
hirsutism and infertility with the presence of bilaterally
enlarged ovaries is attributed to Stein and Leventhal
(1935).
However, women with sclerocystic ovaries but without
all, or indeed any, of this triad of clinical features
were first reported by Goldzieher and Green (1962). Some
of these women have hypothyroidism or Cushing's disease
(Yen 1980), suggesting that the characteristic ovarian
morphology may be a common end stage of the ovarian
response to a variety of pathological stimuli.
The availability of radioimmunoassay has facilitated
investigation of these women. Typical endocrine
abnormalities include elevated concentrations in serum of
LH, androstenedione (A) testosterone (T),
dehydroepiandrosterone sulphate (DHEAS) and 17-alpha
hy^roxyprocssterone ~nd -- ->-e J oejt"onc o>"~-uc*"'I'in
(Yen 1980). The orig in of excess sex steroids has been
investigated indirectly by selective stimulation or
suppression of the adrenal (Kirschner et al 1976, Poison
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et al 1988b) or ovary (Chang et al 1983a) and directly by
catheterisation and sampling of the ovarian and adrenal
veins (Kirschner and Jacobs 1971, Wajchenberg et al 1988).
Whilst these studies have shown that the ovary is the
major source of androgens in women with PCO, the relative
contribution of the ovary and the adrenal to the
pathogenesis and persistence of the syndrome continues to
be debated (McKenna 1988).
More recently, high resolution ultrasonographic
examination of the ovary has been applied in the
investigation and management of PCO. The ovarian
morphology in women with PCO, diagnosed by clinical and
biochemical assessment, is heterogenous (Kim et al 1979,
Orsini et al 1985). The ovary is defined as polycystic by
ultrasound if multiple cysts (10 or more) 2-8 mm in
diameter are arranged peripherally around a dense core of
stroma or scattered through an increased amount of stroma,
and is usually enlarged (Adams et al 1986). In a 'normal'
population of women of reproductive age, up to 22 "L may
have ultrasonic features of PCO, although a substantial
proportion of these women have clinical symptoms and signs
such as irregular periods unwanted facial hair
consistent with a mild form of PCO (Poison et al 1988a).
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AETIOLOGY - POLYCYSTIC OVARY SYNDROME
Aetiological factors suggested for the development of
the polycystic ovary syndrome are numerous and have
included:
a) a primary ovarian abnormality (Jacobs 1987);
b) prepubertal adrenal dysfunction (Yen 1980);
c) sustained adrenal hypersecretion of androgens and
then peripheral aromatisation resulting in increased serum
concentrations of oestrone (McKenna 1988);
d) inheritance of a dominant trait with an increased
rate of expression (Hague et al 1988) possibly related to
an effect of maternal androgens upon gonadal development
in utero;
e) differential regulation of the secretion of LH and
FSH by androgenic inhibition of gonadotrophic releasing
hormone (GnRH, Duignan et al 1975), partial pituitary
desensitisation to GnRH (Waldstreicher et al 1988) or
hyperoestronaemia (Chang et al 1982) inducing a deficiency
of the adrenal and ovarian aromatase systems;
f) abnormal secretion of insulin (Taylor et al 1982,
Barbieri et al 1986);
g) abnormalities of ♦"he cpcreb,,ri of insulin-like growth




An association between disturbed insulin and
hyperandrogenism has been recognised for many years. As
early as 1921, Achard and Thiers described the syndrome
'diabete a femmes de barbe', an association between
hirsutism and non-insulin dependent diabetes mellitus
(NIDDM). More recently an association between insulin
resistance secondary to receptor abnormalities and
hyperandrogenism of ovarian origin has been demonstrated
(Kahn et al 1976, Taylor et al 1982, Poretsky and Kalin
1987), and in women with PCO, increased concentrations of
insulin and androgen frequently coexist (Barbieri et al
1988).
Although Taylor et al (1982) suggested that
hyperinsulinaemia may contribute to hypersecretion of
androgens from the ovary in subjects with insulin
resistance, other authors have suggested the converse,
that excess production of androgens may induce
hyperinsulinism in women with PCO (Shoupe et al 1983,
Pasquali et al 1983). Alternatively, increased
concentrations of insu14 o and androgen in women with "CO





Pancreatic glucagon is involved in the development
and maintainance of abnormalities of carbohydrate
metabolism (Unger 1978) including insulin resistance
(DelPrato et al 1987). Insulin resistance and
hyperglucagonaemia coexist in women with non-insulin
dependent diabetes mellitus (Golay et al 1986, Reaven et
al 1987), gonadal dysgenesis (Costin and Kogut, 1985) and
a glucagon-secreting tumour (Boden et al 1978).
Hyperglucagonaemia and insulin resistance also result
from the administration of androgenic drugs to women
(Williams et al 1985,1986).
Page 11
CHAPTER Is RELATIONSHIPS BETWEEN INSULIN AND OVARIAN
FUNCTION
Ovarian steroid secretion and folliculogenesis are
influenced by circulating concentrations of insulin.
Epidemiological data from heterogeneous groups of hypo-
insulinaemic women with untreated or inadequately treated
diabetes mellitus have shown the age at menarche to be 1-2
years later than that of control subjects, that the age of
the menopause appears to be earlier (Bergqvist 1954) and
that amenorrhoea and oligomenorrhoea are more common
(Joslin et al 1925). Menstrual abnormalities are often
corrected by administration of insulin (Djursing et al
1982). Furthermore, in diabetic women administration of
GnRH results in attenuated gonadotrophin responses
(Distiller et al 1982), suggesting that pituitary
secretion of gonadotrophins is impaired. Alloxan-treated
rats which develop insulin-dependent diabetes have a lower
mean ovarian weight than do control animals, and the
ovarian weight is corrected by FSH only when administered
together with insulin (Liu et al 1982).
The pattern of sex steroid hormone levels in women
with diabetes is contentious. Anovulatory women with
diabetes have lower serum concentrations of testosterone
Page 12-
Chapter 1
and oestradiol in addition to gonadotrophins, compared
with anovulatory non-diabetic women (Djursing et al 1982).
However, the same authors have also reported increased
serum concentrations of testosterone and androstenedione
in insulin-treated diabetic women before the menopause
(Djursing et al 1985) but increased levels of oestrogens
and sex hormone-binding globulin (SHBG) after the
menopause (Nyholm et al 1989), when compared with those in
age and weight-matched controls. Interpretation of
hormone values in diabetic women is complicated by the
heterogeneous nature of the condition, particularly with
respect to the sensitivity to insulin and insulin-like
growth factor 1 (IGF-1) (Poretsky and Kalin 1987). It is
apparent, however, that hyperglycaemia or other metabolic
defects associated with hypo-insulinaemia may influence
the hypothalamo-pituitary-ovarian axis independently of
the effects of insulin deficiency.
INSULIN RESISTANCE AND OVARIAN FUNCTION
Insulin resistance is an attenuation of the effect of
insulin upon its target tissue, ^hich in the presence of a




Obesity is the commonest clinical cause of
hyperinsulinaemia and insulin resistance (Kissebah et al
1982, Peiris et al 1986, Olefsky and Kolterman 1981, Clark
et al 1983, Dohm et al 1988). In obese subjects, the
amplitude of each secretory pulse of insulin is increased
(Polonsky et al 1988 a,b), there is a more rapid
pancreatic response to glucose (Doeden and Rizza 1987) and
hepatic clearance of insulin may be reduced (Polonsky et
al 1988b). Obese subjects also have a reduced
hypoglycaemic response to exogenous insulin (Clark et al
1983). Obesity is associated with loss of insulin
receptors and with impairment of post-receptor events
(Clark et al 1983, Felber et al 1987), particularly a
reduction in insulin-mediated glucose uptake (Prager et al
1987). Hyperinsulinaemia, resulting from increased
pancreatic secretion of insulin, does not fully compensate
for insulin resistance in obese subjects, and thus
hyperglycaemia results (Prager et al 1987). In addition,
hyperglycaemia and hyperinsulinaemia may induce a degree
of insulin resistance by receptor or post-receptor actions
or desensitisation (Yki-Jarvinen et al 1987, Ratzmann et
al 1983).
Obesity is often associated with amenorrhoea (Rogers
and Mitchell 1952), although not all obese women have
menstrual disturbances (Zhang et al 1984). Serum
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concentrations of androgens are elevated in obese
oligomenorrhoeic women compared with those in obese
eumenorrhoeic women or in women of normal weight and
matched for age (Friedman and Kim 1985). However,
secretion and clearance rates of androgens are also
increased in obese women (Samojlik et al 1984, Kurtz et al
1987). Although serum concentrations of free testosterone
(free T) are elevated (Evans et al 1983, Wild et al 1983),
those of androstenedione are reduced (Zhang et al 1984,
Grenman et al 1986, Dunaif et al 1988) because of
increased clearance by aromatisation to oestrone (Edman
and MacDonald 1978, Kurtz et al 1987). In obese
eumenorrhoeic women, concentrations of free T correlate
with those of insulin (Dunaif et al 1987) and reduced
hepatic clearance of insulin and reduced peripheral
insulin sensitivity are mediated by increased
concentrations of free T (Peiris et al 1987).
Between 35 and 60% of women with PCO are obese
(Goldzieher and Green 1962, Franks 1989, Conway et al
1989) and women with PCO are commonly obese during
adolescence (Yen 1980). However, obesity itself does not
maintain the polycystic ovarian disorder nor does obesity
affect gonadotrophin release (Dunaif et al 1988), but
weight reduction in obese women with PCO is associated
with a decline in concentrations of testosterone and
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androstenedione and a resumption of ovulatory menstrual
cycles (Bates and Whitworth 1982)
GLUCOSE TOLERANCE AND HYPERINSULINAEMIA IN WOMEN WITH PCO
Women with PCO have a similar fasting concentration
of fasting glucose to that in age- and weight-matched
normal women (Burghen et al 1980, Jailal et al 1987,
Dunaif et al 1987). Obese women with PCO, however, have
significantly greater plasma concentrations of glucose
following administration of a glucose load (Burghen et al
1980, Dunaif et al 1987) and exhibit a 20% incidence of
impaired glucose tolerance or diabetes (Dunaif et al
1987). Non-obese women with PCO have normal glucose
tolerance (Chang et al 1983b, Bruno et al 1985, Dunaif et
al 1987). Epidemiological studies of men and women have
suggested that glucose intolerance is predictive of the
later onset of diabetes mellitus (Medalie et al 1975), but
data about long term glycaemic control in women with PCO
are lacking.
Women with polycystic ovary syndrome (PCO) and
elevated concentrations of circulating androgens are
hyperinsulinaemic and exhibit insulin resistance when
compared with age- and weight-matched control women
(Burghen et al 1980, Chang et al 1983b, Shoupe et al 1983,
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Pasquali et al 1983, Bruno et al 1985, Jailal et al 1987,
Dunaif et al 1987 , Dunaif et al 1989, Dunaif and Graf
1989, Peiris et al 1989a). PCO and obesity have
synergistic deleterious effects upon glucose tolerance
(Dunaif et al 1987, 1989). Both receptor and post-
receptor defects in insulin action have been described
(Shoupe et al 1983, Jailal et al 1987) but neither are
related to the development of or presence of antibodies to
insulin or its insulin receptor (Burghen et al 1980).
Sathanandan et al (1987), however, were unable to
demonstrate decreased sensitivity to insulin in women with
PCO other than that due to obesity.
HYPERANDROGENISM AND GLUCOSE HOMEOSTASIS
An association between hyperinsulinism, insulin
resistance and hyperandrogenism is well established. In
women with PCO, fasting concentrations of insulin and
insulin responses to an oral glucose load have been shown
to correlate with serum concentrations of testosterone and
androstenedione in peripheral (Burghen et al 1980, Chang
et al 1983b, Shoupe et al 1983, Dunaif et al 1987) and
ovarian venous blood (Nagamani et al 1986), although such
relationships have not been consistently demonstrated
(Alper and Garner 1987, Geffner et al 1986). Serum
concentrations of insulin show an inverse correlation
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with those of dehydroepiandrosterone sulphate (DHEAS) in
women with PCO (Schriock et al 1988).
The role of androgens in inducing hyperinsulinaemia
and insulin resistance or, conversely, the role of insulin
in the causation of hyperandrogenaemia, have been widely
investigated. Sex differences in insulin action have
been attributed to higher concentrations of androgens in
men (Yki-Jarvinen 1984, Hale et al 1985), although there
is no difference in the rate of decline in glucose
concentrations, nor concentrations of insulin or glucagon,
during prolonged fasting in men and women (Clore et al
1989), and neither administration of DHEAS to normal men
(Nestler et al 1988) nor suppression of ovarian secretion
by analogues of GnRH, or surgical removal of hyperthecotic
ovaries in hyperandrogenic women (Geffner et al 1986,
Annos and Taymor 1981, Nagamani et al 1986, Leedman et al
1989) alters the insulin status.
Taylor et al (1982) and Barbieri et al (1988)
proposed that insulin augments or stimulates the ovarian
secretion of androgens. Addition of insulin in vitro to
culture media of ovarian stromal cells obtained from
hyperandrogenic women results in the increased secretion
of testosterone and androstenedione (Barbieri et al 1986)
whereas Smith et al (1987) showed that the insulin
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response in vivo to an oral glucose load correlated with
the incremental increase in concentrations of
testosterone, androstenedione and dihydrotestosterone in
those women with the greatest degree of insulin
resistance, but not in control women nor in those with
mild insulin resistance. During hyperinsulinaemic,
euglycaemic clamp studies, however, concentrations of
androstenedione, but not of testosterone, increased in
women with PCO (Stuart et al 1987, Nestler et al 1987,
Dunaif and Graf 1989), indicating that concentrations of
testosterone do not rise acutely in response to insulin
administration in vivo.
LH SECRETION
Ovarian production of androgens is dependent upon LH
stimulation (Kirschner and Jacobs 1971, Givens et al 1974,
Galogero et al 1987). In vitro, LH and insulin act
independently to increase androgen output (Poretsky and
Kalin 1987), whilst insulin potentiates LH-induced
androgen secretion (Cara and Rosenfield 1988). Mean
concentrations of LH in women with PCO are usually
increased (Yen 1980, McKenna 1988, Franks 1989) as a
result of greater amplitude and frequency (Waldstreicher
et al 1988) or amplitude alone (Dunaif et al 1988) of LH
secretory pulses compared with normal women. Lower
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concentrations of LH have been reported in obese compared
with non-obese women with PCO (Paradisi et al 1986) and it
has been suggested that insulin may amplify LH-dependent
secretion of androgens in these women (Pasquali et al
1987, Dunaif and Graf 1989). However, the concentrations
of androgens in these two groups were also similar (Dunaif
et al 1988) despite different concentrations of insulin.
ADRENAL ANDROGENS
Dehydroepiandrosterone (DHEA) is the most abundantly
secreted adrenal steroid. It has a rapid turn-over rate
and is converted to DHEA sulphate (DHEAS) by sulphatases
in all tissues. DHEA is a potent non-competitive
inhibitor of glucose-6-phosphate dehydrogenase; a lack of
DHEA may facilitate more rapid synthesis of
dihydronicotinamide adenine dinucleotide phosphate (NADPH)
and therefore encourage NADPH-dependent lipogenesis.
DHEA and DHEAS, used therapeutically, have beneficial
effects upon diabetes and obesity in experimental models.
DHEA reduces hyperinsulinaemia in genetically obese,
diabetic mice by inhibiting pancreatic secretion of
insulin and increasing tissue insulin sensitivity (Coleman
et al 1982). It also reduces body fat and low density
lipoprotein lipid values in normal men (Nestler et al
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1988) and is believed to slow the development of
atherosclerosis (Gordon et al 1988), the serum
concentrations of DHEAS being inversely correlated to
mortality from cardiovascular disease in men over 50 years
(Barrett-Connor et al 1986).
Adrenal secretion of DHEA and responsiveness to ACTH
are increased in some women with PCO (Lachelin et al 1979,
Alper and Garner 1987, Devesa et al 1987, McKenna 1988).
Fasting concentrations of insulin and DHEAS are
inversely correlated independently of BMI in
hyperandrogenic hyperinsulinaemic women (Smith et al. 1987,
Schriock et al 1988) and those of DHEAS decrease during
prolonged experimental hyperinsulinaemia (Nestler et al
1987), although no relationship between DHEAS and insulin
was demonstrated in hyperandrogenic women by Alper and
Garner (1987). DHEAS may enhance insulin binding to red
blood cells in contrast to the inhibitory effects of
testosterone (Schriock et al 1988).
SEX HORMONE BINDING GLOBULIN (SHBG)
The concentration of free testosterone






Serum concentrations of SHBG are predominantly
regulated by sex steroids, thyroid hormones and IGF-1
(Anderson 1974, Suikkari et al 1988, Plymate et al 1988).
They are also influenced by dietary lipids (Reed et al
1988). SHBG levels are reduced in obesity (Plymate et al
1981, Wild et al 1983), and insulin has been postulated to
inhibit the synthesis of SHBG (Plymate et al 1988). The
relationship between concentrations of insulin and SHBG is
independent of obesity and the androgen levels (Peiris et
al 1989b).
Oestrogen and testosterone stimulate (Lee et al 1987)
whilst both insulin and IGF-1 inhibit synthesis of SHBG
from cultured human hepatoma cells (Plymate et al 1988,
Hamilton-Fairley et al 1989).
In non-obese women with PCO, concentrations of SHBG
are inversely correlated to those of insulin (Shoupe and
Lobo 1984, Dunaif et al 1987). Consumption of a low
calorie diet results in an increase in SHBG values and a
reduction in concentrations of insulin and IGF-1 (Kiddy et
al 1989) while reduction in insulin concentrations by
administration of diazoxide is accompanied by a rise in
those of SHBG (Nestler et al 1989).
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GLUCAGON AND GLUCOSE HOMEOSTASIS
Several counterregulatory hormones, including
adrenaline, Cortisol and growth hormone, impair insulin-
mediated metabolism of glucose and have been implicated in
deterioration of glucose tolerance. In contrast,
relatively few data concerning the effects of
hyperglucagonaemia on insulin action, particularly upon
peripheral tissues, have been reported.
Glucagon may contribute to abnormalities of insulin
action (Unger 1978). Hyperglucagonaemia is associated
with a modest impairment of glucose disposal in insulin-
sensitive peripheral tissues in normal subjects (Rizza et
al 1979, Bajorunas et al 1986, DelPrato et al 1987), and
induces resistance to the suppressive effects of insulin
on basal hepatic glucose output by the liver, primarily by
an inhibition of insulin-mediated glycogen synthesis
(DelPrato et al 1987). In contrast, in subjects with
diabetes and hypoglucagonaemia secondary to pancreatectomy
or pancreatic disease, tissue sensitivity to insulin is
increased (Nosadini et al 1982).
Insulin is a potent inhibitor and regulator of
glucagon secretion (Maruyama et al 1983). During
experimental hyperinsulinaemia, pancreatic release of
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glucagon is suppressed less than in that of insulin,
possibly as a result of impaired intra-islet regulation
(Wu and Ho 1987).
Insulin resistance is associated with
hyperglucagonaemia in subjects with gonadal dysgenesis
(Costin and Kogut 1985), obesity (Borghi et al 1984), a
glucagon-secreting pancreatic tumour (Boden et al 1978) or
non-insulin dependent diabetes mellitus (Reaven et al
1987). Administration of danazol or oxymetholone
(Williams et al 1985, 1986) also results in
hyperinsulinaemia and insulin resistance, and these
effects have been attributed to hyperglucagonaemic
actions of these drugs (Williams et al 1985, 1986).
Peripheral concentrations of glucagon are a reliable
indicator of glucagon secretion by the pancreas under
euglycaemic conditions (Herold and Jaspan 1986), although
the liver is an important organ for glucagon extraction
from the portal vein (Jaspan et al 1984). The portal-to-
peripheral ratio for the biologically active 3,500 Dalton
fraction of plasma glucagon is 2.7:1 in the basal state
(Jaspan et al 1984). There is marked intra-subject
variability in basal plasma concentrations of glucagon
(Jaspan et al 1981).
Page
Chapter 1
Glucagon concentrations in androgenised women with
PCO have not previously been studied.
ENDORPHIN
Beta-endorphin is an important regulator of the
release of GnRH and thus of gonadotrophins, modulating
androgenic inhibition of GnRH release in normal women
(Vermesh et al 1987, Cumming et al 1984, Jewelewicz 1984).
It has been suggested that women with PCO may have an
aberration of opioidergic control of GnRH secretion
(Cumming et al 1984) , serum concentrations of beta-
endorphin are elevated in obese hirsute women with PCO
(Givens et al 1980, Aleem and Macintosh 1984) and a
positive correlation was demonstrated with body weight,
although not in normal women (Aleem and Mcintosh 1984).
In addition, concentrations of beta-endorphin in ovarian
follicular fluid are greater than those in plasma,
particularly in fluid obtained from women with polycystic
ovaries (Aleem et al 1987).
Beta-endorphin has been isolated from pancreatic
islets (Bruni et al 1979) where it stimulates the release
of insulin and glucagon (Reid and Yen 1981, Reid et al
1984). Intravenous infusions of beta-endorphin induces a
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marked rise in peripheral concentrations of insulin and
glucagon in obese subjects, whereas non-obese subjects
responded with an increase in concentrations of glucagon
only (Giugliano et al 1987a,b, Paolisso et al 1987).
PROLACTIN
Hyperprolactinaemia, which induces mild glucose
intolerance and hyperinsulinaemia also decreases glucose
transport in cultured adipocytes from pregnant (ie
hyperprolactinaemic) rats without affecting insulin
receptor binding (Ryan and Enns 1988) and has, therefore,
been implicated in the development of insulin resistance
associated with pregnancy (Ryan et al 1985).
Concentrations of prolactin are increased in 7-15%
in women with PCO (Franks 1989). Prolactin may thus
contribute to impaired glucose tolerance and
hyperinsulinaemia in some women with PCO.
INSULIN-LIKE GROWTH FACTOR 1 (IGF-1)
IGF-1 has a structural homology to insulin and
stimulates target cells by binding to insulin or IGF-1
receptors. IGF-1 activity is modulated by IGF-binding
protein (IGF-BP, placental protein 12), circulating levels
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of which are insulin dependent (Suikkari et al 1988) and
which are reduced in women with PCO (Pekonen et al 1989).
High-affinity IGF-1 receptors have been demonstrated
in human ovaries (Bayer et al 1986). In vitro studies
have shown that IGF-1 stimulates accumulation of
testosterone and androstenedione from the ovarian stroma
of a woman with hyperandrogenism as efficiently as does
insulin, whereas relaxin and IGF-2 had no effect (Barbieri
et al 1986), and IGF-1 augments LH-induced secretion of
androgens from the ovary (Cara and Rosenfield 1988).
Barbieri et al (1988) and Dunaif et al (1989) have
proposed that insulin may stimulate ovarian production of
androgens in hyperandrogenic women by cross-reacting with
IGF-1 receptors. In rats, however, sustained
hyperinsulinaemia did not increase androgen
concentrations, although IGF-1 binding sites increased in
number suggesting that insulin may influence ovarian IGF-1
receptors (Poretsky et al 1988).
SUMMARY
A close relationship between ovarian function and
insulin has been demonstrated. In some subjects with
increased concentrations of androgens and insulin
resistance, hyperglucagonaemia also coexists, and has
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been proposed to be responsible for abnormalities of
insulin action. Concentrations of beta-endorphin in obese
women with PCO are increased, suggesting a possible effect
upon the pancreas to increase glucagon secretion.
The study was initiated to investigate the role of
glucagon in insulin resistant hyperandrogenic states, and
to establish whether alteration of androgen values
influenced those of insulin and glucagon. Chapter 2
describes the methodology used and subjects recruited for
the study, whilst Chapters 3 and 4 describe the basal
concentrations and glucose-stimulated responses of
glucose, insulin, C-peptide and glucagon in relation to
those of gonadotrophins and sex steroids. In Chapter 5,
the changes in concentrations of gonadotrophin and sex
steroids in response to administration of antiandrogens,
androgens and antigonadotrophins are described, whilst
the effects of these changes upon basal and stimulated
glucose, insulin, C-peptide and glucagon values are
examined in Chapter 6. The hypothesis is discussed and
conclusions are drawn in Chapter 7.
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CHAPTER 2: MATERIALS AND METHODS
SUBJECTS WITH PCO:
Forty-four women aged 20-33 years and with a
diagnosis of PCO (the "PCO group", subjects 1-44; Table
2.1) based upon the presence of four out of five of the
following criteria, were recruited for study:
a) Amenorrhoea or oligomenorrhoea, with the history of
menstrual disturbance usually dating from the menarche.
b) Ultrasonographic features of PCO as defined by the
criteria of Adams et al (1986). In 8 subjects, where the
ultrasonographic appearances were not wholly typical
(Orsini et al 1985) inspection of the ovary during
operative laparoscopy confirmed the presence of enlarged
sclerocystic ovaries, although biopsy and histological
examination were not performed.
c) Clinical evidence nf hyperandroge™ is^1 indicated by
the presence of hirsutism or acne. Hirsutism was defined
as hair more profuse, coarser, darker or longer than































































































































































































































































































































proximal limbs, abdomen, chest or back, and quantified by
the criteria of Ferriman and Gallwey (1961). Each area
was assessed scored up to 4 points to provide a maximum
score of 36. Acne was defined as the presence of a typical
pustular rash affecting face or upper thorax.
d) Elevation of the serum concentration of luteinising
hormone (LH) on two occasions one week apart taken without
regard to the timing of the menses, with a normal
concentration of follicle stimulating hormone (FSH).
e) Elevation of one or more of serum concentrations of
testosterone (T) , androstenedione (A) or
dehydroepiandrosterone sulphate (DHEAS).
All women underwent clinical, gynaecological and
biochemical assessment and women with ovarian or adrenal
tumours or Cushing's syndrome were excluded. Two women
had acanthosis nigricans of the neck and axillae (Matsuoka
et al 1987) and serum prolactin was mildly elevated in two
women (Subjects Nos. 8 and 21) at 912 and 751 IU/L
respectively (normal range 125-crN° IU/L).
Thirty three women underwent a one hour
adrenocorticotrophic hormone (ACTH) stimulation test (New
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et al 1983) with the concentration of 17-
hydroxyprogesterone (170HPo) measured immediately before
and 60 minutes after intramuscular injection of 250
micrograms Synacthen (Ciba Laboratories, Horsham, Sussex).
The first sample was obtained between 0800 and 0900 h. ,
without regard to the timing of the menses. In four of
the 11 women who did not undergo the Synacthen test,
congenital adrenal hyperplasia due to 21-hydroxylase
deficiency had been excluded previously by a similar
Synacthen stimulation test.
These clinical and biochemical details are shown in
Table 2.1. All subjects were euthyroid and none was known
to have any abnormality of glucose tolerance or blood
pressure. No medication known to affect glucose tolerance
or sex steroid levels had been taken in the three months
preceding the study.
CONTROL SUBJECTS
Sixteen women with laparoscopically diagnosed mild
endometriosis, ie, an American Fertility Society score
less than 15 (American Fertility Society, 1985) and
presenting with infertility and/or pelvic pain, and 7
women with uterine leiomyomata awaiting hysterectomy
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served as control subjects (the "control group", subjects
45-67; Table 2.2). All had a regular menstrual cycle of
length 23-36 days and elevated concentrations of
progesterone greater than 25 nmol/1, consistent with
ovulation, during the luteal phase. Ultrasonography in
the follicular phase of the menstrual cycle or laparoscopy
confirmed normal ovarian morphology. None of these
subjects showed clinical evidence of androgen excess nor
acanthosis nigricans. All subjects had normal serum
concentrations of testosterone, androstenedione, prolactin
and thyroxine. None of the control subjects was known to
have any abnormality of glucose tolerance or blood
pressure and no medication known to affect glucose
tolerance or sex steroid levels had been taken in the
three months preceding the study.
Subjects were weighed in indoor clothing after an
overnight fast and those with a body mass index (BMI, body
weight in kg/height in m^) greater than 25.0 kg/m^ were
defined as obese. This index of obesity was used
because it correlates well with the percentage of body fat
and is the most satisfactory simple index of obesity
based upon body weight and height (Reid and Van Vugti. J O O N. O
1987). Where indicated, obese subjects were subdivided
into those "overweight" with a BMI between 25.0-29.9 kg/m^
and those more obese with a BMI greater than 30.0 kg/mz*
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The study was approved by the hospital ethical
committee and all subjects gave written, informed consent
to participation.
CLINICAL DETAILS.
The mean age in each of the control groups was
greater than that of the women with PCO. Twenty-four of
the 44 women with PCO (58%) were obese (BMI >30 kg/m2
16 women) and 10 of the 23 control subjects (43%) were
obese (BMI >30 kg/m^ in 4 women). The BMI in the
corresponding obese study and control groups were equally
matched, as were those for the non-obese groups.
In all the women with PCO, the basal concentration of
170HPo was within the normal range (<10 nmol/L) and in
none was the maximum concentration of 170HPo in response
to ACTH stimulation in excess of 20 nmol/L (Table 2.1).
ULTRASONOGRAPHY
All ultrasound examinations were performed by the
author using the full bladder technique with a Diasonics
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DS1-RF sector scanner with a 3.5MHz general purpose probe
(Adams et al 1986).
The number of follicles seen in the greatest
longitudinal plane and the maximum follicular diameter
were recorded. The stromal density was assessed
subjectively on a scale 0,+ or ++. The diameters of each
ovary were measured in three planes, and the ovarian
volume calculated from the formula for a prolate ellipsoid
(Orsini et al 1985) (volume = x D2 x D3 x 0.5233 cm^),
where D-^ , D2 and D3 are the three maximum longitudinal,
antero-posterior and transverse diameters. In 7 subjects,
only one ovary, and in 2, neither ovary, were seen.
The mean (SD) ovarian volume in subjects with PCO
(n=30) was 15.7 (4.7) mm^ (range, 7.4-29.2 mm^) (Table
2.1). Measurements of ovarian volume were not made in 12
women with PCO and no measurements were possible in 2
further women. The mean ovarian volume in non-obese,
normal women during the early follicular phase of the
menstrual cycle, using the same method of measurement has
been found to be 6.7 (2.3) mm^ (n=22) (G. Shaw, P.J.





All women consumed a weight maintaining diet
containing approximately 300g carbohydrate for 3 days
before the study.
An oral glucose tolerance test (oGTT) was performed
by the author using a 75g glucose load, commencing between
08.30 and 09.30 h after an overnight fast of 12h. The
glucose was consumed over 10 minutes as a flavoured drink
in 300ml water. The test was undertaken in the early to
mid-follicular phase of the cycle (days 1-10) in control
subjects, but without regard to the menses in the subjects
with PCO.
Venous blood samples were obtained through an
indwelling catheter sited in an antecubital vein. Samples
of 20 ml. were obtained 30 and 15 mins and immediately
prior to the ingestion of the glucose load and further
samples were obtained 30, 60, 90, 120 and 150 min
thereafter.
Patency the venous catheter was maintained by
flushing with 0.5ml N.saline containing 25u/ml sodium
heparin after each blood sampling. On completion of the
oGTT, the catheter was withdrawn.
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Blood for measurement of glucose and HbA-^ was
collected into commercial sodium fluoride tubes and
assayed the same day. LH, FSH, T, A, DHEAS and SHBG
concentrations were measured in pooled equal volumes of
fasting serum. Serum was separated within one hour and
stored at -20C until assayed. The free testosterone index
(free T) was calculated from the equation:
free T = (total T/SHBG) x 100 (Pollock and Ratcliffe
1987).
Serum for measurement of insulin and C-peptide
concentrations was separated within lh and stored at -20C
until assayed. Blood for measurement of pancreatic
glucagon concentrations was drawn into ice-cold lithium
heparin tubes containing 0.04 ml trasylol, 400 KIU/1
(Bayer, Newbury, Berks). The plasma was separated by
centrifugation, frozen within 7 minutes, and stored at
-20C until assayed. Insulin, C-peptide and glucagon
concentrations were measured in all samples taken from
time 0 to the completion of the oGTT, except in 10 women
in whom glucagon was measured at times 0 and 120 min only.
TRF\TMEMrt PROTOCOLS
After completion of the oGTT, women in the PCO group
were allocated non-randomly to one of three treatment
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groups, in accordance with their therapeutic requirements
as described in Chapter 5. Women in the control groups
were allocated by computerised randomisation to one of two
treatment groups (Chapter 5). The treatment regimes were
designed to alter serum gonadotrophins and/or sex steroids
in order to determine the effects of these upon insulin,
glucose and glucagon homeostasis. An oGTT was performed
in an identical manner to that described above.
ASSAY METHODS
Plasma glucose was measured by the glucose oxidase
method described by Brunsman (1973). HbA-^ was measured by
a cation exchange analysis at 415nm (Parker et al 1981).
Insulin was measured by the radioimmunoassay (RIA)
method of Hales and Randall (1963), with an intra-assay
coefficient of variation (CV) of 11%. Results are
expressed in mU/1 of the first World Health Organisation
human insulin standard.
C—peptide was measured by a commercial RTA kit
(Medgenix, Fleurs, Belgium). The intra-assay CV was 15%
at 0.35pmol/l and 7% at 1.36pmol/l.
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Glucagon was measured in unextracted plasma using a
recently available commercial RIA kit (Serono
Laboratories, Welwyn Garden City). The inter- and intra-
assay CV at 125pmol/l were 11% and 7.4% respectively.
Serum testosterone was measured by solid phase double
antibody RIA after chromatographic extraction and ether
extraction (intra-assay CV 5%) (Dowsett 1985, Vaughan
Williams et al 1989).
Concentrations of SHBG were measured by the
immunoradiometric assay method (IRMA) of Hammond et al
(1985) .
Concentrations of DHEAS were measured in unextracted
serum by RIA using an assay kit obtained from Amersham
(Amersham, UK). The inter-assay CV was between 8-12%.
Androstenedione was measured in extracted serum by
1 o trRIA using x JI-labelled androstenedione 3cm-
oxime/histamine produced in Hope Hospital, Salford, and
sheep anti-A(6-conjugate) obtained from Guildhay AntiSera.
TP e inter-assav OV was bptw^on 9-13%.
1 ? s
LH and FSH were measured by RIA using I-labelled
LH and FSH respectively obtained from Chelsea Hospital for
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Women, London, and rabbit anti-LH (F87/2) and anti-FSH
(M93/2) antiserum obtained from Professor Butt,
Birmingham. The inter-assay CV was 4-12% for LH and 7-
15% for FSH.
Samples from each subject were measured in the same
batch to eliminate interassay variation.
STATISTICAL METHODS
Results are presented as the mean (SD) concentration,
although graphs are given with mean (SE) concentrations
for clarity, as results for values of glucagon exhibited a
large variation in SD.
Cumulative totals of glucose, insulin, C-peptide and
glucagon concentrations after oral glucose administration
are the sum of all values from 0 to 150 mins.
Changes in glucose, insulin and glucagon
concentrations over the test period were evaluated using
an analysis of variance (ANOVA) with repeated measures on
one factor (Winer 1981), the factor being study group.
Differences in the HbA^ level between the study groups
were examined using a single factor ANOVA. The
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relationship between HbA-^ and glucose levels (fasting and
summed) was assessed for each study group separately using
Pearson's correlation coefficient.
Comparison of group data for insulin, C-peptide and
glucagon were analysed by Van der Waerden 1-way non-
parametric tests. Pearsons correlation coefficient was
used to compare these values with T, A, DHEAS and SHBG
for any association. ANOVA (F-test) was used to examine
differences between study groups and their interaction.
Changes in T, A, DHEAS, SHBG and free T over the test
period were evaluated by Van der Waerden non-parametric
tests.
Data were anaylsed using the PC/SAS version 6.03
statistical package.
Significance was assumed at the conventional <5%
level.
DISCUSSION
In the investigation of hyperinsulinaemia and insulin
resistance associated with PCO, a number of experimental
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methods have been utilised, including measurement of
insulin concentrations when fasting and in response to
glucose administered orally (Burghen et al 1980, Chang et
al 1983b, Bruno et al 1985, Jailal et al 1987, Dunaif et
al 1987, Smith et al 1987) and intravenously (Billiar et
al 1986), the insulin/glucose ratio (Pasquali et al 1983),
C-peptide values in relation to those of insulin (Pasquali
et al 1982, Bruno et al 1985) and hyperinsulinaemic
euglycaemic clamp studies (DeFronzo et al 1979, Stuart et
al 1987, Peiris et al 1989a, Dunaif et al 1989). The
latter is required for measurement of hepatic and
peripheral insulin sensitivity, whilst the assessment of
insulin secretion rates and hepatic extraction by
measurement of peripheral concentrations of C-peptide is
subject to a number of assumptions, the validity of which
has not been established (Polonsky and Rubenstein 1988).
In studies of the relationships between insulin,
glucagon and androgens, the methodology used for the
measurement of peripheral glucagon levels is of
considerable importance.
Measurement of glucagon in peripheral plasma is
complex. Glucagon circulates in low concentrations and
earlier immunoassays were poorly specific with glucagon
exhibiting molecular heterogeneity (Jaspan et al 1981,
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Valverde et al 1974). The portal-to-peripheral ratio for
immunoreactive glucagon is 1.58, whilst that for the
biologically active 3500 molecular weight fraction is 2.77
(Jaspan et al 1984), although under conditions of
increased glucagon stimulation, greater hepatic extraction
of the 3500 MW fraction is seen. The new assay used in
this study is specific for the 3500 MW fraction and
exhibits minimal cross-rectivity for entero-glucagon and
other glucagon-like activity detected by earlier assays
(I. Laing, personal communication).
In 10 subjects, measurements of glucagon were taken
at times 0 and 120 minutes only. Thereafter, glucagon
assays were performed in blood samples taken at each time
interval. This change was introduced to enable a better
understanding of changes of glucagon values with time
after oral glucose loading, and to allow appropriate
comparison with insulin to be made. Excluding the
glucagon data from the first 10 subjects did not
significantly affect the mean values of glucagon at times
0 and 120 minutes, and they have therefore been included
in the full analysis.
The study was designed to investige the insulin and
glucagon responses to changes in the androgenic
environment induced by various drug therapies, and thus
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the marked inter-subject variability in concentrations of
glucagon did not influence the interpretation of data. As
no attempt to infer absolute sensitivity to insulin or
glucagon in liver or peripheral tissues was necessary,
the euglycaemic technique was not utilised for the
investigation.
It was not possible to measure C-peptide values in
the whole study population. To avoid analytical errors in
applying complex correlation coefficients to small
numbers, C-peptide data were used only to confirm trends
in insulin values between groups.
BODY MASS INDEX (BMI)
Obesity itself influences concentrations of insulin,
androgens and glucagon in peripheral plasma (Borghi et al
1984), and both PCO and control groups were therefore
divided into obese (BMI >25kg/m^) and non-obese sub¬
groups. However, those with a BMI between 25 and 30kg/m^
are "overweight" whilst those with a BMI greater than
30kg/m^ are truly "obese", and further limited analyses of
data in Chapters 3 an^ 4 using these subdivisions of BMT
were undertaken, although some of these subgroups
comprised small numbers of subjects, increasing the
possibility of analytical errors.
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The BMI value at which any division is set is
arbitrary. Studies reporting variation in hormone values
attributable to obesity have used masssively obese women
for investigation (Grenman et al 1986). In studies of
women with PCO, those with a BMI >25kg/m2 (Conway et al
1989, Franks 1989), >27kg/m2 (Pasquali et al 1987),
>28kg/m2 (Pasquali et al 1986, Nestler et al 1989) and
>29kg/m^ (Bruno et al 1985) have been included in the
"obese" sub-groups, whilst in most North American
reports, a body weight >120% of normal (equivalent to BMI
>30kg/m2) has been used (Dunaif et al 1987, 1988).
It has been shown that body morphology has effects
upon insulin resistance, glucose tolerance and sex hormone
secretion (Evans et al 1983). Most studies have not
included waist-hip measurements as an index of body
morphology and insufficient numbers of subjects in the
current study were assessed using these measurements.
Page if]
CHAPTER 3: BASAL STUDIES IN NORMAL WOMEN AND IN WOMEN
WITH PCO.
INTRODUCTION.
Women with PCO have fasting concentrations of
glucose similar to those in age and weight-matched normal
women, but are comparatively hyperinsulinaemic and exhibit
insulin resistance (Burghen et al 1980, Chang et al 1983b,
Shoupe et al 1983, Pasquali et al 1983, Bruno et al 1985,
Jailal et al 1987, Dunaif et al 1987, Dunaif et al 1989,
Dunaif and Graf 1989, Peiris et al 1989a). Elevated serum
concentrations of insulin and insulin resistance may be
associated with excessive secretion of androgens from the
ovary (Barbieri et al 1986).
In women with PCO, the fasting concentration of
insulin and concentrations of A and T may be related
(Burghen et al 1980, Chang et al 1983b, Shoupe et al 1983,
Dunaif et al 1987) although these relationships have not
been demonstrated by others (Alper and Garner 1987,
r,pffn°r et al 1086^. Ovarian production of androgens is
dependent upon LH stimulation (Kirschner and Jacobs 1971,
Givens et al 1974, Calogero et al 1987) but insulin itself
may have a gonadotrophic function also (Poretsky and Kalin
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1987). Mean LH concentrations in women with PCO, which
are usually elevated (Yen 1980, McKenna 1988, Franks
1989), may be weight-dependent (Paradisi et al 1986)
although this has been disputed (Dunaif et al 1988, Franks
1989, Conway et al 1989).
Hyperglucagonaemia is associated with insulin
resistance in subjects with gonadal dysgenesis (Costin
and Kogut 1985), obesity (Borghi et al 1984), glucagonoma
(Boden et al 1978) and non-insulin dependent diabetes
mellitus (Reaven et al 1987) but glucagon concentrations
in women with PCO have not previously been investigated.
Measurement of glycosylated haemoglobin (HbA-^) has
been used to monitor glycaemic control (Jovanovic and
Peterson 1981) and assist in the diagnosis of diabetes
mellitus (Bolli et al 1980). Elevated levels of HbA-^ in
diabetes mellitus are correlated with the development of
diabetic complications (Knuiman et al 1986).
This chapter describes gonadotrophin and androgen
values in the women with PCO and those in age- and weight-
matched control subjects, and relates these to basal
concentrations of glucose, insulin, C-peptide and
glucagon. The relationship between basal concentrations
of glucose and those of HbA-^ was examined to assess the
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value of HbA^ estimation for monitoring glycaemic control
in women with PCO.
METHODS
Details of the subjects recruited and methodology
used are described in Chapter 2. Clinical details for the
study groups are summarised in Table 3.1.
RESULTS
GONADOTROPHINS AND ANDROGENS
Concentrations of LH in serum in obese and non-obese
women with PCO did not differ but, as expected, were
greater than those in the control groups (p<0.01) (Table
3.2). Concentrations of FSH were similar in all groups.
In all women with PCO, the ratio between the
concentrations of LH and FSH was 3.0:1 compared with a
ratio of 1.6:1 in control women (p<0.001, Chi-Squared
i-es^. TP© ratio? "°re simi 1 ar in obese and non-obese

































































































































































































As expected, concentrations of T, free T, and A were
greater in women with PCO than in control women (p<0.01)
(Table 3.2). Non-obese women with PCO exhibited higher
concentrations of T, DHEAS and SHBG than did obese women
with PCO (p<0.05), but concentrations of free T and A were
similar (Table 3.2).
BLOOD GLUCOSE, SERUM INSULIN, C-PEPTIDE, GLUCAGON AND
HbA1.
Fasting concentrations of glucose were similar in all
groups (Tables 3.3 and 3.4). The fasting concentration of
insulin was greater in obese women with PCO than in
control subjects (p<0.05), although only in those with BMI
>30kg/m^. Those in non-obese and "overweight" women with
PCO were similar to the control values (Table 3.4).
The ratio between insulin and glucose values was
greater in obese women with PCO than in the control
subjects (p<0.05), whereas the ratios were similar in non-
obese women with PCO and in control subjects (Table 3.3).
C-peptide data were available in 8 non-obese and 9
obese women with PCO and in 10 non-obese and 6 obese

























































































































































































were greater in obese than in non-obese women with PCO
(p<0.05) and than those in control women (p<0.05, Table
3.3).
Fasting concentrations of glucagon were similar in
women with PCO and control subjects and in obese and non-
obese subjects (Table 3.3), and in women with a BMI
between 25-29.9 kg/m^ and in those with a value >30 kg/m^
(Table 3.4).
Glycosylated haemoglobin was measured in 27 of the
women with PCO (14 obese and 13 non-obese) and in 17 of
the control group (9 obese and 8 non-obese, Table 3.3).
In no case was the HbA^ concentration above the upper
limit of normal for the laboratory (7.2%) and HbA-^
concentrations did not differ between the groups. No
significant correlation was found between HbA^ and fasting
glucose values (r=-0.18, p=0.28).
RELATIONSHIP BETWEEN INSULIN AND GLUCAGON AND OTHER
HORMONAL VALUES.
Analyses are presented for the study subjects as a




In the study population as a whole, fasting insulin
values correlated with the BMI (r=0.38, p<0.01) and free T
values (r=0.40, p<0.005), and inversely with values of
SHBG (r=-0.35,p<0.01, Table 3.5). There were no
significant relationships between concentrations of
insulin and those of T, A, DHEAS or LH.
In non-obese women with PCO, the concentrations of
fasting insulin were related to those of DHEAS (r=0.55,
p<0.01). No relationship was shown between insulin levels
and those of T, free T or A in these women. No
relationship was demonstrated between the fasting
concentrations of insulin and other measurements in these
women.
Similarly, no relationship was demonstrated between
insulin and BMI or between insulin and any hormone
measurements in obese women with PCO, nor in either non-
obese or obese normal women; in particular there was no
relationships demonstrated between values of insulin and
those of glucagon in any group, or by division of obese
groups into those with BMI less than and greater than 30
kg/m .
Fasting values of glucagon were inversely related to




















































































































































































































































































































those obese women with PCO with BMI greater than 30 kg/m^,
but were unrelated to the BMI and to serum concentrations
of androgens, SHBG and gonadotrophins in all other groups
(Table 3.6).
For the study population as a whole, the
concentration of LH was closely related to those of A
(r=0.41, p<0.001), free T (r=0.35, p<0.01), SHBG (r=-0.36,
p<0.005), and weakly to total T values (r=0.25, p<0.05)
(Table. 3.7). However, there was no such correlation in
either group of women with PCO, nor in normal women.
The relationship between concentrations of LH and
fasting insulin values in women with PCO is shown in
Figure 3.1. In only 4 subjects were values of both LH
and insulin greater that 2SD above the mean, whilst, in
the remaining subjects, values of one or both were within
the normal range. The relationship between
concentrations of LH and glucagon in women with PCO is
shown in Figure 3.2. An inverse relationship between
values of LH and BMI was demonstrated in obese women with










































































































































Figure 3.1: Relationship between serum concentrations of
LH and those of insulin in women with PCO. The mean+2SD
concentrations of LH and insulin for control women are
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The variability of clinical and biochemical features
of women with PCO is well recognised (Yen 1980, Goldzieher
1981, Franks 1989, Conway et al 1989).
Despite a careful selection procedure, the endocrine
results indicate that the study group of women with PCO
were not a uniform population. The serum concentration of
LH in women with PCO varies rapidly as a consequence of
wide pulse amplitude (Waldstreicher et al 1988, Dunaif et
al 1988) such that a single sample may not accurately
reflect the mean concentration of LH. Of women with
ultrasonically-diagnosed PCO, 44-51% will have a random
basal LH value within the normal range, although a higher
proportion will have increased mean LH values if sampled
frequently over an 8 hour period because of the greater
amplitude of LH pulses (Waldstreicher et al 1988, Franks
1989, Conway et al 1989). The method chosen in this study
for determining mean LH and androgen values, from pooled
samples obtained three times over a period of 30 minutes,
may not thus accurately reflect mean LH values. LH
concentrations were within the normal range (less than 9SD
above the mean for the control women) in 17 (38.6%) of the
44 women with PCO on the day of sampling, all of whom had
previously demonstrated an elevated basal LH value on at
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least one occasion. The sampling frequency, however,
represented a compromise between a single basal result and
multiple sampling over several hours.
Nevertheless, the mean concentrations of LH, total
and free testosterone and androstenedione were
significantly greater in the PCO groups than those in
control women and compatible with the biochemical profile
of PCO (Yen 1980). Thus, the women selected for the PCO
groups represented an androgenised study population.
Although Orsini et al (1984) described four types of
ovarian ultrasonographic appearance in women with PCO
diagnosed on biochemical criteria, Adams et al (1986)
based the diagnosis of PCO on typical morphological
appearances of the ovary, and showed a close relationship
with menstrual and clinical features associated with the
syndrome (Franks 1989). The ultrasound investigation of
ovarian morphology of obese women with PCO is difficult
because of interposition of adipose tissue. Vaginal
ultrasonography, in which the distance between the ovary
and transducer is reduced, overcomes the problem, but was
no1- available to the author. Assessment of ovarian
morphology in the obese women was, therefore, less
accurate than in the non-obese. However, as the study was
of biochemical and endocrinological features of PCO, and
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not the morphological changes in the ovary in response to
treatment, less importance was placed upon the
morphological compared with the biochemical
characteristics for the fulfilment of recruitment criteria
to the study.
The control subjects formed a heterogenous group.
Most of these women had been shown, laparoscopically, to
have minimal degrees of endometriosis, whilst the
remainder were awaiting surgery for menstrual disorders
secondary to leiomyomata. However, the biochemical
profiles of this group were normal except for reduced
concentrations of SHBG in the obese subjects, although
associated non-hormonal effects of endometriosis such as
immunological changes (El-Roeiy et al 1988) might have had
unrecognised influences upon the results.
The groups were not matched for age, which has
effects upon insulin resistance (Reaven 1988). However,
as the control women were older than the women with PCO,
any differences demonstrated in insulin values between the
two groups would have been expected to be even greater.
Nevertheless, there may be potential confounding effects
of age upon glucagon levels in the control groups that
cannot be assessed on the basis of data obtained in this
study. The obese and non-obese PCO groups were of similar
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age, however, and the comparison between these groups
remains valid.
Fasting and glucose-stimulated hyperinsulinaemia have
been consistently described in women with PCO (Barbieri et
al 1988) affecting those women with associated acanthosis
nigricans most severely (Dunaif et al 1987 , Kahn et al
1976). Women with PCO and acanthosis nigricans are
considered to be a subgroup of PCO but do not have a
distinct endocrine disorder (Dunaif et al 1987), and have
therefore been included in the PCO group in this study.
For women with PCO, mean fasting insulin levels and
the ratio between insulin and glucose were elevated only
in the obese group compared with weight-matched women,
indicating resistance to insulin in obese women with PCO.
The fasting concentration of C-peptide demonstrated a
similar pattern to that of insulin. These was no
difference between the groups in the fasting concentration
of glucagon.
Elevated serum values of insulin have been
demonstrated in a number of studies to correlate with the
serum concentrations of total T and A (Burghen et al,
Chang et al 1983b, Shoupe et al 1983, Bruno et al 1985,
Jailal et al 1987, Pasquali et al 1986, Dunaif et al 1987,
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Schriock et al 1988) and free T (Shoupe and Lobo 1984).
However, no relationships were demonstrated between the
fasting concentrations of insulin and concentrations of T
or A, in contrast to these reports. Similarly, there were
no correlations between the concentrations of LH and those
of T, A, free T or SHBG in any of the groups of women.
This is discussed further in Chapter 4.
An inverse relationship was demonstrated between
fasting concentrations of glucagon and those of
testosterone and androstenedione in obese (BMI >30kg/m^)
women with PCO, but not in any other group. This result
is discussed further in Chapter 4 after presentation of
oGTT data.
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CHAPTER 4: RESPONSE TO ORAL GLUCOSE IN NORMAL WOMEN AND
WOMEN WITH PCO.
INTRODUCTION
Women with PCO have similar basal concentrations of
glucose to age and weight-matched normal women (Burghen et
al 1980, Jailal et al 1987, Dunaif et al 1987, Chapter 3),
but obese women with PCO have increased glucose levels
following a glucose load (Burghen et al 1980, Dunaif et al
1987) and PCO and obesity may have synergistic deleterious
effects upon glucose tolerance (Dunaif et al 1987, 1989).
Several epidemiological studies have suggested that
glucose intolerance is predictive of the development of
diabetes mellitus (Kannel et al 1979, Knuiman et al 1986).
A glucose load provides a stimulus to insulin release and
suppression of release of glucagon in normal subjects
(Borghi et al 1984) thereby permitting an examination of
the relationships between the summed values of glucose,
insulin and glucagon and the serum concentrations of
androgens gonadotrophins.
The insulin response to oral glucose may be related
to serum concentrations of testosterone and
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androstenedione in a similar manner to fasting
concentrations of insulin (Burghen et al 1980, Chang et al
1983b, Dunaif et al 1987, Chapter 3). The suppression of
plasma concentrations of glucagon in response to an oral
glucose load is inhibited in insulin resistant obese
subjects (Borghi et al 1984), but the response of glucagon
to a similar glucose load in women with PCO has not been
examined.
In order to determine whether glucagon is implicated
in the development of hyperinsulinaemia and insulin
resistance associated with PCO, glucose, insulin and
glucagon responses to an oral glucose load were
investigated in two groups of women with PCO. Responses
were also related to circulating concentrations of
gonadotrophins, androgens and C-peptide in an attempt to
determine the role of glucagon and insulin in the
hyperandrogenism associated with PCO.
METHODS
0beOQ and non~nHese ^■"vnen w'.fh PCO and weight-matched
control women, in the same groups as described in Chapters
2 and 3, underwent an oral glucose tolerance test (oGTT)
as described in Chapter 2. Clinical details of these
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women are given in Tables 2.1 and 2.2. The subjects in
obese groups were further classified into those with a BMI
o
less than or greater than 30 kg/m where indicated.
Cumulative totals of glucose, insulin, C-peptide and
glucagon concentrations after oral glucose administration
are the sum of all values from time 0 to 150 minutes.
These are described in Table 4.1.
RESULTS
BLOOD GLUCOSE, SERUM INSULIN, C-PEPTIDE, GLUCAGON AND
HBA1.
Glucose reponses to oral glucose loading in the four
groups of women are shown in Figures 4.1 and 4.2, and
summed values in Table 4.1. In obese women with PCO,
the glucose concentration 60, 90 and 120 minutes after
glucose loading and the summed glucose concentration
during the oGTT were greater than the corresponding values
in non-obese women with PCO (p<0.05) and those in the
control gro"gs a1'"houg1^ division of the obese groups
revealed that this applied only to those women with PCO
and BMI greater than 30 kg/m^ (Figure 4.3, Table 4.2).





























































































































































































































































































































glucose tolerance, as defined by the criteria of the
National Diabetes Data Group (1979).
Insulin concentrations in obese women with PCO 30,
60, 90 and 120 minutes after glucose loading and the
summed insulin value were greater than in non-obese women
with PCO (p<0.05) and in weight-matched control subjects
(p<.05)(Figures 4.4 and 4.5). The summed insulin value
was also greater in non-obese women with PCO than in non-
obese control subjects (p<0.05) (Table 4.1). Further
analysis showed insulin concentrations were greatest in
women with PCO and BMI >30kg/m^ (Figure 4.6, Table 4.2).
The ratio between summed values of insulin and those
of glucose was greater in the PCO groups than in weight-
matched controls (p<0.05) and was greater in obese than in
non-obese women with PCO (p<0.05).
The number of subjects in whom C-peptide was measured
was too small for analysis at each time point. C-peptide
values in control women and in women with PCO are shown
in Figures 4.7 and 4.8 respectively. The summed C-peptide
value was greater in obese vomert with PCO than that in
non-obese women with PCO (p<0.05) and that in the control

































































































































































































Obese women in the control group had a significantly
greater glucagon response to oral glucose loading than did
non-obese control subjects and women in both PCO groups
(p<0.05) (Figures 4.9 and 4.10). However, there was a
wide variation in the concentrations of glucagon within
each of the study groups. Glucagon values at 60-150
minutes were significantly lower in subjects in PCO groups
and in non-obese control subjects than those when fasting
and 30 minutes after glucose loading (p<0.05). With
further analysis, both obese control subgroups (less than
and greater than 30 kg/m2) had greater values of glucagon
at 60, 90 and 150 minutes than PCO groups and non-obese
control women (Figure 4.11).
RELATIONSHIP BETWEEN SUMMED GLUCOSE, INSULIN AND GLUCAGON
VALUES AND OTHER HORMONAL MEASUREMENTS.
Analyses are presented for the whole study population
and for each of the four groups of women (Tables 4.3 and
4.4).
In the study group as a whole, summed insulin values
correlated with the BMT ( r=0.^7, d<0-001) and free TJ i. /
values (r=0.38, p<0.005) and inversely with SHBG (r=-0.35,
p<0.005). No correlations were seen between summed






















































































































































































































































































































































































































































































In non-obese women with PCO, however, summed insulin
values correlated weakly with BMI (r=0.47, p<0.05) and
were inversely related to SHBG values (r=-0.46, p<0.05)
(Table 4.3). In obese women with PCO the summed insulin
values correlated with those of free T (r=0.53, p<0.05),
although this continued to hold only for women with BMI
<30 kg/m^ (r=0.77, p<0.05) but not for the more obese
subgroup (r=0.13, p=0.64).
No relationship between summed insulin values and
other measurements was demonstrated in the PCO nor in the
two control groups and there was no relationship between
insulin and summed glucagon values in any of the groups.
The relationships between the LH values and summed values
of insulin and of glucagon were similar to that for
fasting values (Figures 4.12 and 4.13)
The summed value of glucagon was inversely related to
total T (r=-0.66, p<0.001) and A concentrations (r=-0.59,
p<0.005) in obese women with PCO but not in non-obese
women with PCO or in the control groups (Table 4.4). These
relations continued to hold for women with PCO with BMI
>30 kg/m^ (total T, r=-0.63, p<0.02; A, r=-0.67, p<0.01)
but not in the less obese subgroup. No other
relationships were seen between summed glucagon and other
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Figure 4.12: Relationship between serum concentrations of
LH and summed concentrations of insulin in women wiPlflO.
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Figure 4.13: Relationship between serum concentrations of LH and
summed concentrations of glucagon in women with PCD.
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No significant correlations were found between HbA-^
and summed glucose values (r=0.056, p=0.74). HbA-^
results were markedly skewed, however, by data from one
woman with a diabetic glucose tolerance curve (National
Diabetes Data Group 1985) and who, inexplicably, had the
lowest HbA^ result of all the women studied. When data
from this patient were excluded, a significant positive
correlation between HbA^ and summed glucose levels was
apparent (r=0.389, p=0.02, Figure 4.14).
DISCUSSION
Hyperinsulinaemia, previously demonstrated in women
with PCO (Burghen et al 1980), has been confirmed in this
study. Summed glucose and insulin values were greater in
obese subjects with PCO than in non-obese women with PCO
and weight-matched control women, and in 2 (8%) of these
women impaired glucose tolerance was demonstrated.
Nevertheless, concentrations of glucagon in response to
glucose decreased significantly in women with PCO and in
the control group of normal weight women, although not in
obese normal women, and an inverse relationship between
the glucagon response and the concentrations of total T




















































Elevated androgen concentrations in women with PCO
may be responsible for the development and maintainance of
hyperinsulinaemia and insulin resistance (Burghen et al
1980, Shoupe et al 1983). However, the higher insulin
concentrations and insulin resistance associated with
elevated androgen concentrations in women with PCO does
not occur in men in whom concentrations of androgens are
much greater (Yki-Jarvinen 1984). Furthermore, prolonged
administration of testosterone or androstenedione to
female Rhesus monkeys does not significantly alter insulin
sensitivity (Billiar et al 1986). This suggests that
androgens, at least alone, are not the cause of altered
insulin homeostasis in women with PCO.
Hyperinsulinaemia induces defects in insulin action
(Clark et al 1983) and peripheral insulin resistance in
women with androgen excess may result from associated
increases in insulin levels. No mechanism for androgen-
mediated hyperinsulinaemia has been identified, although
Peiris et al (1989) proposed that in hyperandrogenic women
with PCO, the anabolic effect of androgens may result in a
selective increase in the proportion of insulin-resistant
fast twitch muscle fibres. In the rat, however, the
actions of androgens upon muscle are independent of those
of insulin (Hager and Kalkhoff 1989).
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Conversely, insulin may be responsible for or
contribute to increased androgen production in women with
PCO (Taylor et al 1982). Barbieri et al (1986, 1988) and
Dunaif and Graf (1989) suggested that insulin may act
directly upon ovarian insulin receptors (Jarrett et al
1985) or upon those of insulin-like growth factor 1 (IGF-
1) (Poretsky et al 1985, Bayer et al 1986) to stimulate
production of androgens. In support of this hypothesis,
prolonged hyperinsulinaemia has been shown to increase
binding to and the numbers of IGF-1 receptors in rat
ovarian stroma (Poretsky et al 1988), whilst in vitro
studies have demonstrated the production of androgens by
ovarian stroma from hyperandrogenic women in a dose-
dependent manner (Barbieri et al 1986, Poretsky and Kalin
1987). However, sustained hyperinsulinaemia in
hyperandrogenic women does not stimulate production of
testosterone from the ovary in vivo (Nestler et al 1987,
Stuart et al 1987, Dunaif and Graf 1989).
The relationship between insulin, and ovarian
production and serum concentrations of androgens, is
complex (Dunaif et al 1988). Although fasting and summed
insulin were related to free T ratios in the study
population as a whole, this did not apply to any
individual group of PCO or control subjects except for the
correlation between the summed concentration of insulin
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and free T in the obese women with PCO, and even this
applied only to "overweight" but not more obese women with
PCO. Correlations between concentrations of insulin and
testosterone or androstenedione have been demonstrated
(Burghen et al 1980, Chang et al 1983b, Shoupe et al 1983,
Pasquali et al 1983, Bruno et al 1985, Jailal et al 1987,
Dunaif et al 1987) but not confirmed by others (Geffner et
al 1986, Alper and Garner 1987, Sathanandan et al 1988).
Most studies that have demonstrated a relationship between
testosterone and insulin have been smaller than this and
have, therefore, been subject to possible statistical
error, whilst larger studies are inconsistent in their
conclusions (Dunaif et al 1987, Pasquali et al 1983). The
differences may also reflect differing criteria for
selection of subjects.
Maintained elevation of circulating concentrations of
insulin using hyperinsulinaemic euglycaemic clamping
methods (DeFronzo et al 1979) has been shown to cause an
acute increase in the concentrations of A but not of T in
women with PCO (Stuart et al 1987, Nestler et al 1987,
Dunaif and Graf 1989). The disparity between the
responses of A and T has not been explained, but
attributed to a shortage of substrate, a preferential
secretion of A, or to time-dependent changes in the effect
of insulin upon the ovary (Dunaif and Graf 1989). A more
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prolonged hyperinsulinaemic stimulus did not increase
ovarian secretion of androgen by the ovary in rats,
although insulin and IGF-1 receptor numbers were
increased (Poretsky et al 1988). In contrast,
administration of diazoxide, which inhibits endogenous
insulin release, to obese women with PCO, also resulted
in decreased concentrations of free and total T, but no
change in A, SHBG or DHEAS levels (Nestler et al 1989).
The decreased concentration of T was attributed to a
diazoxide-induced reduction in insulin stimulation of the
ovary.
In contrast to the findings of Schriock et al (1988),
there was no confounding close relationship between
insulin and testosterone to influence that existing
between insulin and DHEAS in the PCO groups. This study
is not able to determine any influence of DHEAS upon
tissue sensitivity to insulin, and no relationship was
demonstrated between DHEAS and insulin in any group.
Pasquali et al (1987) proposed that as concentrations
of LH were lower in obese than non-obese women, the action
of insulin on th~ ovary in non-obese "omen with PCO may be
additive to that of LH whereas in obese women, by
contrast, insulin alone may be sufficient to sustain the
increased ovarian secretion of androgens. However, in
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this study, LH values in obese and non-obese women with
PCO were similar and there was no relationship between BMI
and serum LH concentrations. Indeed, the concentrations
of T, but not of A, was lower in obese than in non-obese
women with PCO, in contrast to that associated with simple
obesity, whereas had LH and insulin effects been additive,
obese subjects with PCO would have been expected to have
higher concentrations of androgens.
Only two of the subjects with PCO had a minor
increase in prolactin concentration, confirming that
prolactin is not implicated in the insulin resistance of
the majority of women with PCO.
GLUCAGON AND INSULIN RESISTANCE IN PCO
In this study fasting and glucose-induced
concentrations of glucagon were similar in obese and non-
obese women with PCO and in non-obese control women,
despite significant differences in concentrations of
insulin and insulin resistance. Thus, the hypothesis of
elevate^ serum conce^^ra ti~ns of glucagon in women witho o
PCO is not supported.
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The greater response of glucagon in the obese than in
non-obese normal women confirms the effect of obesity upon
glucagon concentrations (Borghi et al 1984). Glucagon
values did not decrease in response to glucose in this
group, as they did in women with PCO and non-obese control
subjects. Thus, the mechanism responsible for insulin
resistance and hyperinsulinaemia in women with PCO
differs from that responsible for insulin resistance
associated with obesity (Borghi et al 1984), NIDDM (Reaven
et al 1987), gonadal dysgenesis (Costin and Kogut 1985)
and glucagonoma (Boden et al 1978), in all of which
conditions hyperglucagonaemia co-exists. Indeed, Dunaif
et al (1989) considered that PCO is associated with a
unique disorder of insulin action.
Although resistance of pancreatic alpha-cells to
insulin may explain the failure of glucose to suppress
glucagon secretion in obese subjects (Borghi et al 1984)
the data from this study indicate normal reactivity of
pancreatic alpha-cells to insulin in women with PCO
despite associated insulin resistance.
The normal response of glucagon to glucose in the
hyperandrogenic women in this study is consistent with a
lack of hepatic insulin resistance, resistance to insulin
only occurring within the peripheral tissues. Sustained
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hyperglucagonaemia, in contrast, is a feature of syndromes
associated with both hepatic and peripheral insulin
resistance, such as non-insulin dependent diabetes
mellitus (Reaven et al 1987) and gonadal dysgenesis
(Costin and Kogut 1985), and with administration of drugs
such as danazol (Williams et al 1985) and synthetic
androgens (Williams et al 1986) which induce insulin
resistance and have prominent hepatic metabolism. Peiris
et al (1989a) showed insulin resistance in hyperandrogenic
women to be the result of peripheral but not hepatic
resistance to the action of insulin. This would be
consistent with the findings of this study. However,
Dunaif et al (1989) suggested that peripheral and hepatic
insulin resistance coexist in PCO. Subtle abnormalities
of glucagon in women with PCO may not have been detected
by this study, particularly as assessment of hepatic
extraction or secretion rates of glucagon could not be
assessed.
A relationship between concentrations of total
testosterone and androstenedione and those of glucagon in
the basal state and in response to oral glucose was shown
for the obese women with PCO, and in particular the group
with a BMI in excess of 30 kg/m^. The number of women in
these groups was sufficient to permit statistical
comparison with only small risk of chance error.
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Nevertheless, interpretation of these relationships is
complicated by demonstrating mean concentrations of total
testosterone, androstenedione and glucagon similar to
those in non-obese women with PCO although the latter
group did not exhibit similar relationships. The results
suggest that as concentrations of total testosterone and
androstenedione increase, those of glucagon decrease, a
pattern of response opposite to that proposed or which has
been identified in other hyperglucagonaemic states. These
data do not establish whether testosterone and
androstenedione directly influence concentrations of
glucagon in plasma, therefore serum concentrations of
androgens were altered therapeutically and the influence
upon concentrations of glucagon re-examined (Chapters 5
and 6).
GLYCOSYLATED HAEMOGLOBIN IN PCO
This study has demonstrated that obese women with PCO
have a significantly greater blood glucose response to
oral glucose loading in comparison with that in non-obese
women with PCO and weight-matched normal women. Dunaif
et al (1987) found a 20% incidence of impaired glucose
tolerance in an obese group of women with PCO (mean body
weight 154%), whilst this study found an incidence of 2 of
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24 women (8%)(mean BMI, 32.5kgm-^). These women were not
previously recognised as having any abnormality of glucose
tolerance.
HbA-^ and fasting glucose concentrations did not
differ significantly between the PCO and normal women. A
significant positive correlation between HbA^ and summed
glucose values was demonstrated, but only after exclusion
of data from one patient with extreme values.
Measurement of HbA^ is less sensitive than the OGTT
for the full assessment of glycaemic control. However, an
OGTT is a time-consuming investigation, which would not be
performed in the normal investigation of women presenting
with symptoms suggestive of PCO except in the research
environment, and which assesses acute glycaemic responses
only. HbA^ concentrations, however, reflect levels of
blood glucose over a more prolonged interval (Bunn et al
1976). It was hoped to be able to demonstrate that
assessment of the concentration of HbA-^ would be of value
in the screening of women with PCO to easily select those
who would be at an increased risk for abnormal or impaired
glucose tolerance, and who could then undergo further
investigation of glycaemic control.
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These data have demonstrated, however, that the
measurement of HbA^ is not sufficiently discriminatory to
enable identification of impaired glucose tolerance in
PCO. However, the overall incidence of impaired glucose
tolerance in the subjects was low. If subjects with high
fasting or 1 hour blood glucose values were selected for
further study, the incidence of elevated HbA-^ values may
be higher. Nevertheless, the HbA-^ values suggest that in
the physiological state, despite the presence of
hyperinsulinaemia and insulin resistance, abnormal mean 24
hour glucose levels are not a significant feature of most
obese women with PCO. This suggests that
hyperinsulinaemia is a secondary response to insulin
resistance, rather than a response to impaired glycaemic
levels.
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CHAPTER 5: SERUM GONADOTROPHINS AND SEX STEROIDS IN
RESPONSE TO TREATMENT WITH ANTIGONADOTROPHINS, ANDROGENS
OR ANTIANDROGENS IN NORMAL WOMEN AND WOMEN WITH PCO
INTRODUCTION
Many studies have demonstrated that alteration in the
sex steroids and gonadotrophins in women, by treatment
with antigonadotrophins, sex steroids or antiandrogens,
influences glucose tolerance and insulin levels (Yen and
Vella 1965, Spellacy et al 1972, Beck et al 1975, Cole and
Kitabchi 1978, Gossain et al 1983, Shoupe et al 1983, Wynn
and Godsland 1986).
Cyproterone acetate (CPA) is a derivative of
hydroxyprogesterone used in the treatment of hirsutism and
acne. It possesses anti-androgenic, progestational, anti-
oestrogenic and anti-gonadotrophic properties and reduces
Co
synthesis and secretion of glucocorticoids when used in
high doses (Neumann 1987). Alone, or in combination with
ethinyl oestradiol (35-50 micrograms daily), CPA induces a
rapid fall in the serum concentrations of total T, free T,
A, DHEAS, LH, FSH, oestrone and oestradiol and an increase
in the concentration of SHBG (Falsetti et al 1987,
Couzinet et al 1986).
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Spironolactone has complex anti-androgenic activity,
including inhibition of 17-hydroxylase and 17,20-lyase
activity in the adrenal and ovary. It also increases
aromatase activity, thereby decreasing concentrations of
total T and A of ovarian and adrenal origin (Young et al
1987). It is effective in the treatment of hirsutism in
women with PCO (Givens 1985) although it has adverse
oncogenic effects associated with long term use in animals
(Committee of Safety of Medicines, 1988).
Treatment with analogues of gonadotrophin releasing
hormone (GnRH) results in a state of hypogonadotrophic
hypogonadism in normal women and in those with PCO, after
an initial stimulation interval lasting for up to 14 days
(Calogero et al 1987). The decrease in the secretion and
peripheral concentrations of T and A may be less than
that of oestradiol in the same woman (Rittmaster 1988).
Analogues of GnRH induce a similar degree of suppression
of endometriosis as does treatment with danazol (Tummon et
al 1989). The GnRH agonist analogues are effective in the
treatment of menorrhagia due to uterine leiomyomata and in
suppression of gonadotrophin and ovarian activity in women
with PCO (Chang et al lQ83h, Fleming et al 1985, Lanzone
et al 1987, Steingold et al 1987, Couzinet et al 1986,
Calogero et al 1987).
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Danazol, widely used for treatment of menorrhagia and
endometriosis, is a synthetic non-steroidal testosterone
derivative structurally related to oxymetholone and
possesses complex androgenic activity (Bevan et al 1984).
By high-affinity binding to androgen receptors on sex
hormone-binding globulin (SHBG), the androgen binding
capacity of SHBG is markedly reduced.
This chapter examines the influence of therapeutic
modulation of gonadotrophins and androgens by
antigonadotrophins, androgens or antiandrogens in normal
women and in those with PCO.
METHODS
Women in the PCO groups were allocated non-randomly
to one of three treatment groups, in accordance with
their therapeutic requirements (Table 5.1). Twenty-six
women received cyproterone acetate 2 mg and ethinyl
oestradiol 35 micrograms ['CPA/EE'](Dianette, Schering
Health Care, Burgess Hill, Sussex) daily for 21 days,
recommencing after a 7 day drug-free interval. Six women
received spironolactone, lOOmg twice daily, whilst 9 women
received buserelin ([D-ser (But)^] LHRH-(1-9)-ethylamide,
Suprefact, Hoescht, Hounslow, Middlesex), 1200 micrograms
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intranasally in divided doses daily, and 3 women received
no treatment.
Women in the control groups were allocated to one of
two treatment groups, selected by computer-randomised
programme (Table 5.1). Six women received danazol
(Sterling Winthrop, Guildford, Surrey) 400mg daily, and 10
women received goserelin depot (C-ser(But)^, azgly^-
GnRIl, Zoladex, ICI Pharmaceuticals, Alderley Edge,
Cheshire), 3.6 mg subcutaneously, every 28 days. Seven
women with leiomyomata received no treatment.
After 42 days, all the women receiving treatment were
studied, with blood samples taken in an identical manner
to pre-treatment studies. Samples from each subject were
measured in the same batch to eliminate interassay
variation.
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TABLE 5.1: OPTIONS FOR TREATMENT FOR STUDY SUBJECTS.
TREATMENT GROUP SUBJECT NUMBER TOTAL (n)
PGO SUBJECTS
Cyproterone acetate/ 3, 4, 7, 12, 15, 16,
ethinyl oestradiol 17, 18, 20, 21, 23,
25, 26, 27, 28, 31,
32, 33, 35, 36, 37,
38, 39, 41, 42, 43 26
Spironolactone 10, 19, 22, 30, 34, 40 6_
Buserelin 2, 5, 8, 9, 11, 13,
14, 24, 44 9
CONTROL SUBJECTS
Danazol 45, 50, 54, 58, 61, 62 6
Goserelin 46, 47, 48, 52, 53,




The mean body mass index before treatment did not
differ between the two treatment groups (Table 5.2).
During the treatment period, the median BMI in the
danazol-treated group increased by 2.1%, equivalent to an
O
increase in the BMI of O^kgm-^ but there was no change in
the BMI in the goserelin-treated group (Table 5.2).
Concentrations of LH, FSH, total T, A, free T, DHEAS
and SHBG in serum before and during treatment with danazol
or goserelin are shown in Table 5.3. Before treatment,
there was no difference in values between the two groups.
The concentration of LH in the goserelin-treated group
decreased to 4.6 (2.6) iu/1, lower than in the danazol-
treated group (7.9 (1.9) iu/1, p<0.01). Concentrations of
total T and A remained unchanged in the goserelin group
but decreased in the danazol-treated subjects (total T,
1.9 (0.7) to 1.3 (0.5) nmol/1; A, 5.8 (1.7) to 4.5 (1.8)
nmol/1 respectively, p<0.05). The mean concentration of
SHBG was markedly reduced in danazol-treated subjects from
65 (33) to 9 (10) nmol/1 (p<0.01) and there was a
corresponding increase in the calculated free testosterone


























































































































































































































concentration did not change in the goserelin-treated
group. No change was apparent in DHEAS values in either
group.
PCO SUBJECTS.
Clinical data for the 3 groups of women with PCO,
treated with CPA/EE, spironolactone or buserelin, are
shown in Table 5.4. No significant change in BMI was
observed in any group during treatment.
Concentrations of LH, FSH, total T, A, free T, DHEAS
and SHBG in the serum in the three groups before and
during treatment are shown in Table 5.5. LH and FSH
values decreased in the women treated with CPA/EE and
buserelin but did not change in those treated with
spironolactone. Treatment with CPA/EE markedly reduced
values of total T from 3.6 (1.3) to 2.5 (1.2) nmol/1, A
from 13.9 (5.3) to 7.2 (4.9) nmol/1, DHEAS from 8.0 (2.9)
to 5.6 (1.5) micromol/1 and free T from 12.2 (6.1) to 1.7
(5.9) units!., and increased those of SHBG from 34 (14) to
162 (41) nmol/1 (p<0.001 for all values). In buserelin-
treated subjects, values of total T were reduced from 2.9
(1.4) to 2.0 (1.0) nmol/1 and those of A from 12.5 (4.1)
to 9.5 (3.1) nmol/1 (p<0.05), but those of DHEAS, SHBG and
















































































































































































































































































































































































total T from 2.8 (0.8) to 2.1 (0.4) nmol/1 (p<0.01), but
did not affect those of free T, A, DHEAS or SHBG.
DISCUSSION
Significant changes in gonadotrophin and androgen
values occurred in response to administration of danazol
or goserelin to normal women, and cyproterone acetate and
ethinyl oestradiol, buserelin or spironolactone to women
with PCO. The changes are in accordance with other
published reports of the use of danazol (Bevan et al 1984,
Tummon et al 1989), goserelin or other analogues of GnRH
in normal women (Tummon et al 1989), and cyproterone
acetate and ethinyl oestradiol (Couzinet et al 1986,
Falsetti et al 1987), buserelin or other analogues of GnRH
(Chang et al 1983a, Steingold et al 1987) and
spironolactone (Givens 1985, Young et al 1987) in women
with PCO.
Fasting concentrations of glucose, insulin, C-peptide
and glucagon and their responses to glucose were
reassessed in the changed environment during treatment to
determine the role of androgens in the development of
insulin resistance and in modification of plasma
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concentrations of glucagon. The details of these studies
are presented in Chapter 6.
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CHAPTER 6: CHANGE IN GLUCOSE, INSULIN, C-PEPTIDE AND
GLUCAGON RESPONSES TO GLUCOSE LOADING IN NORMAL WOMEN AND
IN WOMEN WITH POLYCYSTIC OVARY SYNDROME DURING MODULATION
OF SERUM ANDROGEN AND/OR GONADOTROPHIN CONCENTRATIONS.
INTRODUCTION
A number of published studies have investigated the
change in glucose and insulin values associated with
alteration of concentrations of androgens in women with
PCO, by treatment with spironolactone (Shoupe and Lobo
1984), an analogue of GnRH (Geffner et al 1986),
ketoconazole (Pepper et al 1987), a combined oral
contraceptive (Cole and Kitabchi 1978) and cyproterone
acetate with ethinyl oestradiol and diet (Pasquali et al
1986).
Other studies have investigated the effects of
experimental hyperinsulinaemia on androgen values in women
with PCO, acutely during an oGTT (Smith et al 1987), by
hyperinsulinaemic euglycaemic clamp studies (Stuart et al
1987, Nestler et al 1987, Dunaif and Graf 1989). and by
inhibition of pancreatic insulin secretion with diazoxide
(Nestler et al 1989).
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The role of androgens in the development of insulin
resistance in women with PCO has yet to be elucidated. As
discussed in Chapter 4, androgens may be responsible for
alteration in peripheral insulin sensitivity (Peiris et al
1989), but insulin may increase secretion of androgens
from the ovary (Barbieri et al 1988). Suppression of
circulating androgens by administration of spironolactone
(Shoupe et al 1983) was associated with a decrease in
fasting and glucose stimulated concentrations of insulin
although there was no correlation found between changes in
concentrations of insulin and total testosterone.
Treatment with analogues of GnRH, which markedly reduces
circulatory concentrations of sex steroids, has no effect
upon the insulin response to glucose (Geffner et al 1986),
and cyproterone acetate does not influence concentrations
of insulin independently from the effects of weight loss
(Pasquali et al 1986).
Combined oestrogen and gestagen contraceptive
preparations have a deleterious effect upon glucose
tolerance which may be related to the progestagen (Wynn et
al 1979) as ethinyl oestradiol alone does not alter
glucose tolerance (Spellacy et al 1972). Even in those
women with normal glucose tolerance, serum concentrations
of insulin are increased (Yen and Vella 1968, Gossain et
al 1983, Wynn and Godsland 1986). Progesterone, unlike
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ethinyl oestradiol, augments glucose-induced release of
insulin from murine pancreatic cells in vitro, possibly by
an alteration of islet cell sensitivity to glucose
(Nielsen 1984).
Binding of insulin to receptors on monocytes or
erythrocytes obtained from non-obese normal women during
the follicular phase of the menstrual cycle is similar to
that during administration of low-dose combined oral
contraception (Tsibris et al 1980). However,
administration of a combination of ethinyl oestradiol and
levonorgestrel induces a temporary state of peripheral
insulin resistance, although without any change in hepatic
sensitivity to insulin or correlation between peripheral
insulin sensitivity and the insulin response to oral
glucose (Skouby et al 1987, Kasdorf and Kalkhoff 1988).
In a woman with PCO and acanthosis nigricans, Cole
and Kitabchi (1978) reported reversal of hyperinsulinaemia
with a combination of mestranol and norethisterone,
although this finding has not been substantiated by
further studies.
Combined oral contraceptives do not affect plasma
glucagon responses to oral or intravenous glucose
administration in normal women (Gossain et al 1983),
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although the response of glucagon to arginine stimulation
is variable (Beck et al 1975, Gossain et al 1983). In
animal studies, administration of gestagen results in
increased portal vein concentrations of glucagon, whilst
administration of oestrogens has the opposite effect
(Mandour et al 1977).
Cyproterone acetate used alone does not appear to
affect serum concentrations of insulin, nor is there a
direct effect upon body weight (Breckwold 1980). In women
with PCO, the combination of CPA (50 trig), ethinyl
oestradiol (30 micrograms) and weight loss resulted in a
fall in serum androgen values, although no correlation was
demonstrated between the change in concentrations of
androgens and either insulin secretion or insulin
resistance, and women with similar weight loss without
other treatment showed an equivalent reduction in fasting
insulin values (Pasquali et al 1986).
In hyperinsulinaemic women with PCO, treatment with
spironolactone resulted in a significant fall in fasting
and glucose-stimulated concentrations of insulin, although
without correlation between "hanges in insulin values and
those of total T (Shoupe and Lobo 1984). Spironolactone
may accelerate glucose utilisation (Evans, personal
communication in Peiris et al 1987). The effects of
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spironolactone upon plasma glucagon values have not been
reported.
The insulin response to oral glucose is not affected
by treatment with GnRH agonist analogues (I.C.I, in-house
data on file) although their effect upon plasma glucagon
values are not known. Geffner et al (1986) reported that
a long-acting analogue of GnRH did not affect fasting or
glucose-stimulated concentrations of insulin in three
women with PCO, although serum values of T, A and
oestradiol were suppressed to castrate levels. Values of
LH were not reported. They suggested that hyperandrogenism
is not responsible for maintainance of hyperinsulinaemia
in women with PCO, although their findings also suggest
that hyperinsulinaemia does not maintain increased ovarian
secretion of androgens in the presence of low serum
concentrations of LH.
Other studies have investigated the effects of
experimental hyperinsulinaemia on androgen values in women
with PCO, acutely during an oGTT (Smith et al 1987), by
hyperinsulinaemic euglycaemic clamp studies (Stuart et al
1987, Nestler e^ al 1987, Dun a if and Graf 1989), and by
inhibition of pancreatic insulin secretion with diazoxide
(Nestler et al 1989).
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Sex differences in insulin action are modest.
Diabetes mellitus is more common in post-pubescent males
than females matched for weight and age (Kannel et al
1979). Insulin-mediated glucose disposal is 45% lower in
men (Yki-Jarvinen 1984), and men have higher plasma
concentrations of insulin but equivalent concentrations of
C-peptide compared with age- and weight-matched women
(Hale et al 1985), illustrating that androgens may mediate
an inhibition of hepatic insulin clearance. In mice, male
animals treated with streptozotocin or by subtotal
pancreatectomy develop diabetes more frequently than
females, and administration of androgens to the females
increases the subsequent frequency of diabetes (Paik et al
1982).
Testosterone therapy has no effect upon fasting
glucose concentrations in normal subjects (Taalat et al
1957) and implants of testosterone or androstenedione
administered to female Rhesus monkeys do not significantly
alter basal or glucose-stimulated insulin or C-peptide
values (Billiar et al 1987). In normal men, DHEAS does
not alter peripheral insulin sensitivity (Nestler et al
198p N.
Several synthetic androgens induce hyperinsulinaemia
and impair glucose tolerance, in contrast to natural
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androgens. Methyltestosterone (McCullagh and Jones 1941,
McCullagh and Lewis 1942), oxymetholone (Woodward et al
1981) and methandienone (Wynn et al 1962) impair glucose
tolerance and induce insulin resistance, whilst
oxymetholone also induces severe hyperglucagonaemia
(Williams et al 1986). These effects are evident in men,
as seen from the development of insulin resistance
associated with use of anabolic steroids in powerlifters
(Cohen and Hickman 1987).
During treatment with danazol, hyperinsulinaemia,
insulin resistance and hyperglucagonaemia develop
independently of any associated weight gain although basal
insulin concentrations are not increased (Wynn 1977,
Gottenberg et al 1982, Williams et al 1985, Vaughan
Williams et al 1989). It has been suggested that
hyperglucagonaemia during danazol treatment contributes to
the development of insulin resistance (Williams et al
1985) via a direct effect upon the pancreas (Gottenberg et
al 1982) although alternatively the "androgenic nature" of
danazol may be responsible (Williams et al 1985, Vaughan
Williams et al 1989).
The data presented in Chapter 5 detailed the changes
in concentrations of gonadotrophins and androgens in
normal women and in women with PCO during treatment aimed
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at modifying the hormonal milieu. Fasting concentrations
of glucose, insulin, C-peptide and glucagon and their
responses to glucose were reassessed in this changed
endocrine environment to determine the role of androgens
in the development of insulin resistance and alterations
of plasma concentrations of glucagon.
METHODS
After completion of the oGTT (Chapter 2), women in
the PCO groups were allocated non-randomly to one of
three treatment groups, in accordance with their
therapeutic requirements, and women in the control groups
were allocated to one of two treatment groups, selected by
computer-randomised programme, as described in Chapter 5
(Table 5.1). After 42 days, all the women receiving
treatment underwent a second oGTT, performed in a manner
identical to that described above. Medications were taken
as normal on the day of the repeat oGTT.
Samples from each subject were measured in the same





Fasting concentrations of insulin and C-peptide were
unchanged during treatment in both obese and non-obese
normal women, but the fasting concentration of glucagon
had increased from 63 (16) to 215 (84) pmol/1 (p<0.01) and
that of glucose decreased from 4.4 (0.4) to 3.8 (0.4)
mmol/1 (p<0.05) in danazol-treated subjects. There was no
change in fasting concentrations of insulin or glucagon in
goserelin-treated subjects (Table 6.1).
The summed concentrations of glucose after glucose
loading did not differ from the respective pre-treatment
values in either group (Table 6.2). However, in the
danazol-treated group, glucose values between 30 and 90
minutes after glucose loading were greater than
corresponding values before treatment (p<0.05), but had
returned to fasting levels by 150 minutes. There was a
marked increase in the insulin response in this group,
values between 30 and 150 minutes after glucose loading
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treatment, p<0.05). The insulin response was unchanged in
goserelin-treated women.
C-peptide data were only available in 4 subjects in
each group. The cumulative C-peptide response to oral
glucose was greater during treatment with danazol, from
11.4 (1.4) to 20.1 (8.5) pmol/1) than during treatment
with goserelin (Table 6.2).
The cumulative glucagon response to oral glucose
increased from 337 (79) pmol/1 to 839 (465) pmol/1 in the
danazol-treated group (p<0.05, Table 6.2) but was
unchanged in the goserelin-treated women.
No relationship was demonstrated between the changes
in the insulin or glucagon response to glucose loading as
a result of danazol or goserelin treatment and the changes
in androgen or LH concentrations in either group.
PCO SUBJECTS
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Treatment with CPA/EE did not alter the summed
concentrations of glucose after glucose loading, but there
was a delay in the return of blood glucose concentrations
to the fasting level, values at 120 and 150 minutes being
greater than respective pre-treatment values. Treatment
with buserelin or spironolactone did not alter fasting
concentrations of glucose (Table 6.3).
None of the treatments influenced the summed values
of insulin, C-peptide or glucagon nor were the responses
to oral glucose changed (Table 6.4).
No relationship between the changes in concentration
of androgen or SHBG and those of insulin or glucagon was
demonstrated in any of the groups.
DISCUSSION
In this study, women were investigated to determine
whether changes in concentrations of androgens influenced
insulin resistance, hyperinsulinaemia and glucagon
responses to glucose stimulation in women with PCO.
Subjects were not randomised to each treatment and,
therefore, although the final composition of the groups
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was similar, no comparative between-group data can be
undertaken with validity.
Reduction of circulating androgens by administration
of an analogue of GnRH had no effect on insulin
concentrations or insulin resistance in women with PCO
despite a marked decrease in total T and A concentrations.
This is in agreement with the findings of Geffner et al
(1986). SHBG values and the calculated free T value were
unchanged during treatment. Conway et al (1989) have
shown that concentrations of total T are greater in women
with infertility and PCO than other subjects with PCO
diagnosed by ultrasonography. In the current study, the
subjects treated with buserelin all complained of
infertility, but had total T values similar to those of
the whole group of PCO subjects.
In addition, as in the control group, there was no
alteration in glucagon values in women with PCO treated
with an analogue of GnRH.
Although obesity, hyperinsulinaemia and LH may act
independently on ovarian androgen secretion (Dunaif et al
1987), the reduction in the concentration of LH during
treatment with GnRH-analogue resulted in a marked
diminution of ovarian androgen production in both normal
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and PCO subjects without change in insulin values or the
BMI. This suggests that, in vivo, insulin alone does not
sustain the excess ovarian secretion of T or A in women
with PCO, in contrast to the findings of in vitro studies
(Barbieri et al 1986).
In spite of decreased circulating concentrations of T
and A, those of insulin, C-peptide and glucagon values
were unchanged. This is consistent with an absence of
influence of T, A or LH on pancreatic, hepatic or
peripheral sensitivity to glucose or insulin. However,
the methods used may not be sufficiently sensitive to
detect small alterations in insulin and glucagon
sensitivity, which may have been exposed using
hyperinsulinaemic-euglycaemic clamp methods (Skouby et al
1987).
The use of an identical analogue of GnRH for subjects
with PCO and control subjects in this study would have
been desirable, to enable a direct comparison between
these groups to be made, but the treatment requirements
and study protocols did not allow this. However, highly
significant reductions in the circulating concentrations
of gonadotrophins were seen in both groups.
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Treatment with spironolactone did not influence
insulin resistance, despite a small decrease in serum
concentrations of total T. This is at variance with the
results of Shoupe and Lobo (1984). The dose of
spironolactone used in this study was twice that used by
Shoupe and Lobo (1984) and was used for six rather than
for two weeks, but the decrease in the concentrations of
total T was similar in both studies. The concentration of
free T was unchanged in response to treatment with
spironolactone in this study, and this may be more
important than total T in tissue sensitivity (Peiris et al
1989a).
Peiris et al (1987) suggested that a decrease in
insulin values in response to administration of
spironolactone may result in an increase in tissue
sensitivity to insulin and thus an acceleration of glucose
utilisation, although no clinical details or methods used
are given to support their conclusions. Improvement in
glucose tolerance in response to both spironolactone and
bromocriptine therapy has been reported (Blum et al 1981)
but in only 2 women with PCO. Prolactin, however, is
known to influence insulin resistance, and bromocriptine




Spironolactone also affects calcium and magnesium
concentrations by its diuretic action and both of these
electrolytes may influence tissue sensitivity to insulin
(Chapter 7).
The decreases in concentrations of testosterone and
androstenedione in the women with PCO during treatment
were not associated with changes in those of glucagon.
Pre-treatment data from women with PCO in the obese
subgroup (BMI >30kg/m^) showed an inverse relationship
between fasting and summed concentrations of glucagon and
those of testosterone and androstenedione (Chapters 3 and
4). However, similar analysis of this subgroup during
treatment is confounded by inclusion of subjects in three
treatment protocols, each potentially influencing
concentrations of glucagon by different action, and none
of the treatment groups alone included sufficient numbers
of subjects for analysis.
The increased insulin response to an oral glucose
load in normal women during treatment with danazol (Wynn
1977, Gottenberg et al 1982, Williams et al 1985, Vaughan
Williams et al 1989) was confirmed although without
change in glucose values. Women treated with goserelin,
however, showed no change in fasting glucose or insulin
values, nor in glucose or insulin responses to glucose
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loading, indicating that goserelin is without significant
effect upon insulin action. This may influence the choice
of drug for the treatment of endometriosis in those women
known to have impaired glucose tolerance (Vaughan Williams
et al 1989).
No correlation has been shown between changes in the
concentrations of testosterone, androstenedione, or free
testosterone and that of insulin associated with the
administration of either danazol or goserelin. The
hypothesis that the danazol-induced increase in the serum
concentration of testosterone is responsible for the
development of insulin resistance and hyperglucagonaemia
cannot be confirmed (Williams et al 1985, Vaughan Williams
et al 1989).
Plasma concentration of glucagon in the fasting state
and in response to an oral glucose load significantly
increased in non-obese normal women during treatment with
danazol. As each subject was used as her own internal
control to exclude effects of varied expression of
immunoreactive glucagon in the plasma (Jaspan et al 1981),
the finding of Williams et al (1985) of severe
hyperglucagonaemia in women taking danazol has been
confirmed and extended. However, women treated with the
GnRH-analogue goserelin, showed no change in the plasma
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concentration of glucagon, demonstrating that treatment
of endometriosis is not, in itself, responsible for
hyperglucagonaemic response to danazol therapy.
Although hyperglucagonaemia was well established
within six weeks of starting treatment with danazol, it is
not possible to say how rapidly this change developed, nor
whether such a change was sustained for the duration of
the treatment period. Although a significant increase in
weight was seen for the danazol-treated group, the
concentration of glucagon was substantially greater than
that in the obese control subjects, suggesting that it was
not the weight itself that was responsible for the rise in
insulin and glucagon levels.
In conjunction with hyperinsulinaemia, an increase in
the concentration of glucagon results in a significant
shunting of infused glucose towards lipid synthesis and
away from glycogen synthesis (DelPrato et al 1987).
Danazol is known to increase plasma concentrations of low
density lipoproteins and decrease those of high density
lipoproteins (Fahraeus et al 1984), possibly as a
consequence of the increased insulin and/or glucagon
values. In contrast, Farrish et al (1989) have shown that
the GnRH-analogue, buserelin, did not alter plasma
lipoprotein concentrations when administered for one year.
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This is consistent with lack of significant effect of
GnRH-analogues and, therefore, endogenous androgens, upon
insulin and glucagon action.
One proposed mechanism for the hyperinsulinaemic
response to danazol is by a direct stimulation of
pancreatic beta-cells (Gottenberg et al 1982). Insulin,
however, is a potent inhibitor of glucagon secretion and
is the principal regulator of glucagon production in the
basal state (Maruyama et al 1984). The development of
insulin resistance in response to administration of
danazol suggests that insulin becomes less effective in
controlling pancreatic glucagon secretion and thereby
enables the development of hyperglucagonaemia. It is
possible, therefore, that danazol-induced insulin
resistance leads to a defect in regulation of the
pancreatic alpha-cell, and thus to the development of
hyperglucagonaemia.
As confirmed in this study, administration of danazol
is associated with a decrease in the serum concentration
of SHBG (Bevan et al 1984), probably due to an inhibition
of hepatic synthesis (Gershagen et al 1984), and thus a
modest rise in calculated free testosterone concentration.
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In vitro, testosterone stimulates (Lee et al 1987)
whereas insulin inhibits (Plymate et al 1988) synthesis
of SHBG. The data in this study do not allow further
elucidation of whether changes in concentrations of SHBG
in vivo results from a direct action of danazol or an
inhibitory effect of insulin.
The changes in concentrations of insulin and glucagon
when fasting or in response to an oral glucose load
following treatment with either danazol or ethinyl
oestradiol and cyproterone acetate are complex. One cannot
easily distinguish the direct effects of these drugs on the
secretion of insulin and glucagon, and any change in
insulin and glucagon secretion which may be secondary to
alteration in the secretion of ovarian and adrenal
s teroids.
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The results of these studies suggest that the
mechanisms responsible for insulin resistance differs in
androgenic conditions of differing aetiology. The lack
of a hyperglucagonaemic response to glucose in women
androgenised as a result of PCO suggests a different
mechanism for insulin resistance in those women from that
associated with androgen administration, non-insulin
dependent diabetes mellitus and obesity, conditions which
are associated with hepatic and peripheral insulin
resistance. The increase in concentrations of insulin
and glucagon which resulted from treatment with danazol do
not appear to be caused directly by increased androgen
concentrations.
However, the mechanism for insulin resistance in
women with PCO has not been clarified. No consistent
relationships between fasting or glucose-stimulated
concentrations of insulin, glucagon or glucose and
concentrations of androgens were demonstrated, confirming
the lack of a simple relationship between concentrations
of insulin and androgens. Changes in serum concentrations
of oestrogens, which may modify those of androgens,
insulin or glucagon, were not measured in this study,
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although no relationship to concentrations of androgens or
insulin in hyperandrogenic women with PCO was demonstrated
by Dunaif et al (1987).
An inverse relationship between concentrations of
glucagon and those of testosterone and androstenedione was
demonstrated in the obese women with PCO, but not in non-
obese or "overweight" women with PCO nor in the control
groups. This pattern of response is the opposite to that
proposed or to that seen in other states of insulin
resistance and hyperglucagonaemia, but it is not possible
to establish the possible mechanisms for this unexpected
finding from these data. Nevertheless, a decrease in
serum concentrations of androgens by therapeutic
manipulation did not appear to influence circulating
concentrations of glucagon in hyperandrogenic women.
Serum concentrations of beta-endorphin are increased
in obese, hirsute women with PCO (Givens et al 1980, Aleem
and Mcintosh 1984). In obese normal subjects, beta-
endorphin infusion results in increased secretion of
insulin and glucagon, whereas in non-obese subjects, an
increase in glucagon concentrations only is seen
(Giugliano et al 1987). Although the glucagon status in
obese women with PCO was normal despite elevated
concentrations of beta-endorphin, the responsiveness of
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the pancreas to beta-endorphin appeared to be diminished
compared with that in obese normal women (Givens et al
1980, Aleem and Mcintosh 1984). Hyperinsulinaemia in
obese women with PCO is, therefore, probably not secondary
to beta-endorphin stimulated increased pancreatic
secretion of insulin. In addition, the increased
incidence of glucose intolerance in obese women with PCO
(Dunaif et al 1987) does not appear to be related to beta-
endorphin, as apparently is the case in obese normal women
(Guigliano et al 1988). Nevertheless, opiate blockade by
naloxone or nalmefene reduces insulin levels by
approximately 25% without influence upon those of glucose
in women with PCO (Givens et al 1987). The action of
opiate antagonists on the pancreas in these women may also
be influenced by alterations in the hypothalamo-pituitary
axis (Berga and Yen 1989).
Hyperglucagonaemia contributes to the development of
abnormalities of insulin action (Unger 1978) and is
associated with impairment of both hepatic and peripheral
disposal of glucose (DelPrato et al 1987). In the
presence of hyperinsulinaemia, increased concentrations of
glucagon promote lipid formation rather than glycogen
storage (DelPrato et al 1987), and plasma concentrations
of lipoproteins and triglycerides tend to increase. Women
with PCO have increased plasma concentrations of free
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fatty acids (FFA) and very low density lipoproteins
(VLDL), although these do not correlate with serum
concentrations of androgens (Mattsson et al 1984, Wild et
al 1985). With normal peripheral concentrations of
glucagon and normal suppression of glucagon secretion by
glucose, the data presented here suggest that increased
concentrations of FFA and VLDL in women with PCO are not
related to abnormalities of glucagon secretion. Golay et
al (1986) have shown that glucagon is not responsible for
increased FFA concentrations of obese individuals when
compared with non-obese subjects.
Despite hyperinsulinaemia and insulin resistance,
HbA-^ values did not indicate significant hyperglycaemia in
most women with PCO, and this index is not of value for
monitoring subtle abnormalities of carbohydrate metabolism
in these subjects.
In most insulin resistant states, changes in the
number and function of insulin receptors appear to have a
regulatory function (Clark et al 1983, Kahn and White
1988), since they are improved by treatment of the
disease. Increases in the number and sensitivity of
receptors as a result of decreased concentrations of
insulin has been proposed as an explanation for reduced
ovarian secretion of androgens in response to treatment
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with diazoxide (Nester et al 1989) or weight loss
(Pasquali et al 1986). However, other treatments for
symptoms of hyperandrogenism in women with PCO do not
appear to be mediated through alteration in ovarian
insulin receptor number or function. In particular,
administration of spironolactone is not accompanied by
significant changes in peripheral concentrations of
insulin or glucose.
The insulin receptor is an insulin-regulated tyrosine
kinase allosteric enzyme, phosphorylating itself and other
substrates on tyrosine residues (Kahn and White 1988).
Alteration in receptor signal transduction could enhance
sensitivity to insulin and has been proposed as a site for
future therapeutic manipulation (Kahn and White 1988).
Insulin effects within the cell may be mediated or
influenced by intracellular calcium (Kissebah et al 1975),
high levels of which are associated with resistance to
insulin action (Draznin et al 1988), although the
influence of changes in concentrations of free calcium on
receptor and post-receptor steps has not been elucidated.
Release of insulin from the pancreas is also a calcium-
dependent process (Hellman 1975), but treatment with
nifedipine, a calcium-channel blocking agent, does not
appear to alter insulin levels or glucose tolerance in
non-insulin dependent diabetics (Collins et al 1987,
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Beable et al 1989). Further studies are needed to
explore the influence of calcium, and also magnesium, on
insulin resistance in women with PCO. Preliminary data
from studies of treatment of women with PCO with
nifedipine show no alteration in concentrations of
androgens or insulin (I.M. Golland, unpublished).
Few prospective longitudinal studies to assess the
consequences of hyperinsulinaemia and insulin resistance
in women with PCO have been undertaken. It is not known
whether there is an increased risk of cardiovascular
disease in obese women with PCO compared with that in
either non-obese women with PCO or obese eumenorrhoeic
women. One study has demonstrated, however, that post¬
menopausal women with abnormal coronary angiography are
more likely to have experienced irregular menses and to be
hirsute than those with normal angiography (Wild et al
1988). Decreased insulin sensitivity associated with a
degree of impaired glucose tolerance in obese women with
PCO, particularly when associated with abnormal
concentrations of circulating lipids (Mattsson et al 1984)
indicates a possible increased risk of atheromatous
vascular disease. These women, however, also have
increased circulating concentrations of oestrogens
resulting from extraglandular aromatisation of androgens
(Yen 1980) or increased secretion from the polycystic
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ovary itself (Wajchenberg et al 1988), and which may
reduce the incidence of vascular disease. Further
prospective studies examining the contributions of
hyperinsulinaemia, hypertension and sex steroids to the
risk of development of atheromatous vascular disease in
women with PCO are required, particularly to consider
whether obesity is an independent risk factor.
The risk of development of hyperplasia and carcinoma
of the endometrium is increased by prolonged exposure to
circulating oestrogens unopposed by progesterone, and the
incidence of endometrial carcinoma has been shown to be
increased in anovulatory women with PCO (Jackson and
Dockerty 1957). It is of interest that in women with
endometrial carcinoma concentrations of insulin are
increased and the women exhibit insulin resistance in
association with stromal luteinisation of the ovaries
(Nagamani et al 1988).
Insulin resistance may be an inherited trait (Reaven
1988). A three-fold variation in insulin sensitivity
between non-obese individuals with normal glucose
tolerance has been demonstrated, with values of peripheral
glucose uptake in the most insulin resistant quartile of a
degree comparable to subjects with impaired glucose
tolerance or non insulin-dependent diabetes mellitus
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(Reaven 1988). Inheritance of an insulin resistance trait
may explain the development of long-term hyperinsulinaemia
and subsequent reduction in insulin receptor number and
diminished post-receptor events (Clark et al 1983). An
increase in concentrations of insulin may act upon the
ovary to increase androgen and IGF-1 production (Barbieri
et al 1988) and/or synergistically with an inherited
abnormality of ovarian control mechanisms or LH secretion
expressed at puberty (Hague et al 1988), thereby
contributing to the induction of the polycystic ovary
syndrome.
The absence of significantly increased concentrations
of glucagon in the peripheral plasma in women with PCO
suggests that the mechanism responsible for insulin
resistance in these women differs from that associated
with administration of androgenic drugs such as danazol,
obesity or non-insulin dependent diabetes mellitus. The
hypothesis, that glucagon counters the influence of
insulin on peripheral tissues but not that on the ovary,
thereby permitting an unopposed gonadotrophic action of
insulin on androgen secretion (Barbieri et al 1988), is
not supported by these studies.
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Lack of predictive value of HbA1
for impaired glucose tolerance in
polycystic ovary syndrome
I. M. Golland, C. A. Vaughan Williams, S. M. Shalet, L. H. Million and M.
Elstein
Departments of Obstetrics and Gynaecology, Endocrinology and Medical Statistics,
University Hospital of South Manchester, Manchester, UK
Abstract
Twenty-seven women with polycystic ovary syndrome (PCO) and
17 control women had a 75 g oral glucose tolerance test (oGTT) per¬
formed. Although glucose tolerance was impaired in the obese (body
mass index > 25 kg/m2) women with PCO, glycosylated hemoglobin
(HbAj) concentrations did not exceed the normal upper limit (7.2%).
In all 44 women, there was no correlation between HbAj and fasting
glucose (r = 0.082, p = 0.63) but there was a significant correlation
between HbA} and summed glucose levels through the oGTT (r =
0.389, p = 0.02). HbAt measurement does not predict the presence of
impaired glucose tolerance in women with PCO.
Introduction
Women with polycystic ovary syndrome (PCO), irrespective of whether they
are obese or not, are hyperinsulinemic both in the fasting state and in response
to oral glucose loading1-4. Obese women with PCO have impaired glucose
tolerance when compared with obese and non-obese eumenorrheic women
with PCO1'4'5, as is shown by significantly higher plasma concentrations of
glucose during oral glucose tolerance testing (oGTT). Obese women with PCO
do not, however, have elevated fasting glucose concentrations, and there is no
constant relationship between the hyperinsulinemic response and the degree of
impairment of glucose tolerance.
The long-term consequences of impaired glucose tolerance and hyper-
insulinemia in PCO are unknown. Insulin might be partly responsible for the
maintenance of excessive ovarian androgen secretion in women with PCO6'7,
but there are no detailed longitudinal studies of the risk of these subjects
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developing diabetes mellitus (DM), vascular disease or hypertension when
compared with women with PCO without abnormal glycemic control. At
present, assessment ofglucose tolerance in these subjects requires that an oGTT
be performed, because measurement of fasting concentrations of glucose and
insulin are not sufficiently discriminatory.
Measurement of glycosylated hemoglobin (HbAi) has been used to monitor
glycemic control8 and assist in the diagnosis ofDM9. Elevated levels ofHbAj in
DM are correlated with the development ofdiabetic complications10. We under¬
took a study, as part of our investigations into the causes of hyperinsulinemia
in obese women with PCO, to establish whether the measurement of HbAj
would be of value in the prediction of abnormalities in glucose tolerance in
women with PCO, and, therefore, be of potential value as a screening test for
a group at potentially increased risk for the development ofDM or complica¬
tions of vascular disease.
Materials and methods
Twenty-seven women, aged 20-34 years (mean 26.7 years), with a diagnosis of
PCO based upon the presence of hirsutism, oligomenorrhea, elevated plasma
LH and LH/FSH ratio, ultrasound evidence ofpolycystic ovaries11, and elevated
serum concentrations ofone or more of the following androgens, testosterone,
androstenedione and dehydroepiandrosterone sulfate, were entered into the
study. Fourteen of these women were defined as obese (OB-PCO), with a
body mass index (BMI, body weight in kg/height in m2) greater than 25. The
remaining 13 women were of normal weight (NOB-PCO, BMI < 25 kg/m2).
None of the women showed evidence of acanthosis nigricans.
Seventeen healthy women, aged 19-45 years (mean 30.7 years), with regular
menstrual cycles and without signs of androgen excess clinically or biochemi¬
cally, served as controls. Nine of these women were obese (OB-control) and
8 were non-obese (NOB-control).
None of the women studied was known to have impaired glucose tolerance,
although 1 woman in the NOB-PCO group had a family history ofDM, and
none had taken any medication known to affect glucose tolerance during the
previous 3 months. The control women were studied during the early or mid-
follicular phase of the menstrual cycle, whilst the PCO women were studied
without regard to the menstrual dates. Irrespective of the day of the cycle,
progesterone measurement at the time of the study confirmed the absence of
recent ovulation.
After a 12-hour overnight fast, a standard 75 g oGTT was performed, with
venous blood samples taken at 0, 30, 60, 90, 120 and 150 minutes for glucose
estimation. HbA) was measured in the fasting sample. Plasma glucose was
measured by a glucose oxidase method, and HbAj was measured by a cation
exchange analysis at 415 nm12. The summed glucose value was obtained from
the sum of all glucose values through the oGTT.
The study was approved by the district ethical committee, and all women
gave their informed consent.
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Statistical analysis
Changes in glucose concentration over the test period were evaluated using a
2-factor analysis of variance (ANOVA) with repeated measures on 1 factor13,
the factors being study group and time. Differences in the HbA] level
between the study groups were examined using a single factor ANOVA. The
relationship between HbA] and glucose levels (fasting and summed) was
assessed for each study group separately using Pearson's correlation coefficient.
Statistical significance was set at the conventional 5% level throughout.
Results
Mean oGTT levels over the test period are presented for each of the study
groups in Figure 1. Fasting glucose concentrations did not differ significantly.
In the OB-PCO women, glucose values were significantly higher at 60 and 90
minutes relative to the non-obese groups and also at 120 minutes relative to the
NOB-PCO women. There was no significant difference between OB-PCO
and OB-control women at any interval during the oGTT. One OB-PCO
woman was found to be frankly diabetic, as defined by the criteria of the
National Diabetes Data Group14.
0 30 60 90 120 ISO
Time (minutes)
Figure 1 Mean (SD) glucose levels in response to 75 g glucose in obese and non-obese
women with PCO and in obese and non-obese control women
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Table 1 Age, body mass index and mean (± SD) HbAi concentrations in plasma in
obese (OB-PCO) and non-obese (NOB-PCO) women with polycystic ovaries, and
in obese (OB-normal) and non-obese (NOB-normal) control women
OB-PCO NOB-PCO OB-normal NOB-normal
Age (range, years) 27.5 25.5 32.6 28.2
(22.6-34.2) (20.9-33.1) (21.0-45.4) (21.7-38.8)
BMI (kg/m2) 31.8 + 4.5 22.6 ± 1.8 30.2 ±3.0 20.8± 2.6
HbAj (%) 5.2 ± 1.0* 5.0 ±0.9* 5.5 ± 1.0* 5.0 ±0.9*
*/= 0.38, p = 0.69
Table 1 shows the age, BMI and HbA] concentration for each of the 4 groups
ofwomen studied. In no case was the HbAi concentration above the upper limit
for our laboratory (7.2%). HbAi concentrations did not differ significantly
between the groups. Non-significant correlations were found between HbAi
and both fasting (r = —0.179, p = 0.28) and summed (r = 0.056, p = 0.74)
glucose values. The results were markedly skewed, however, by the patient
with diabetes who, inexplicably, had the lowest HbAi result of all the women
studied. Excluding this patient again produced a non-significant correlation
between HbAi and fasting glucose, but a significant positive correlation be¬
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Figure 2 Relationship between the concentration ofHbAi and the cumulative concen¬
tration of glucose after 75 g glucose
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Discussion
We have shown in this study that obese women with PCO have a significantly
greater blood glucose response to oral glucose loading in comparison with that
in non-obese women with PCO and non-obese normal women, although not in
comparison with obese normal women. No significant elevation of the fasting
blood glucose above normal limits was seen. These results are in agreementwith
previous studies of obese women with PCO1'4.
HbAj and fasting glucose concentrations did not differ significantly between
the OB-PCO, NOB-PCO and obese and non-obese normal women. A
significant positive correlation between HbAj and summed glucose values was
demonstrated, but only after exclusion of data from 1 patient with extreme
values.
Measurement ofHbAj is less sensitive than the oGTT for the full assessment
of glycemic control. However, an oGTT is a time-consuming investigation,
and one which would not be performed in the normal investigation ofwomen
presenting with symptoms suggestive ofPCO, except in the research environ¬
ment. We hoped to be able to demonstrate that assessment of the concentration
ofHbA] would be ofvalue in the screening ofwomen with PCO, to easily select
those who would be at an increased risk for abnormal or impaired glucose toler¬
ance, and who could then undergo further investigation of glycemic control.
We have demonstrated, however, that the measurement of HbA} is not
sufficiently discriminatory to enable identification ofimpaired glucose tolerance
in PCO. In addition, this would suggest that, in the physiological state, despite
the presence of insulin resistance, abnormal mean 24-hour glucose levels are not
a significant feature ofmost obese women with PCO.
Women with PCO are hyperinsulinemic compared with weight-matched
controls1'4, which implies a variable degree of insulin resistance, although the
underlying biochemical defect is unclear. It has been suggested6'7 that
hyperinsulinemia might be partly responsible for the maintenance of increased
androgen concentrations in PCO as a result of direct stimulation of ovarian
stroma or augmentation of LH-dependent androgen secretion. However, the
greater magnitude of insulin concentrations in obese women is not associated
with similarly increased androgen concentrations17.
Few prospective longitudinal studies assessing the consequences of hyper¬
insulinemia and insulin resistance in these women have been undertaken. It
is not known whether they are at more risk of cardiovascular disease than
non-obese women with PCO or obese eumenorrheic women, although the
male pattern lipoprotein profile seen in androgenized women with PCO16'17
suggests that this might be the case.
In conclusion, the absence of a constant relationship between HbAj and
glucose tolerance in PCO suggests that the measurement of HbAj is not
of value for the prediction of impaired glucose tolerance in these women.
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